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The cost of managing patients with multiple sclerosis at 
Mafraq Hospital
Naila Salem Almazrouei, Omar Abdulla, Palat Chirakkara 
Kumar and Ahmed Osman Shatila
Mafraq Hospital, Abu Dhabi, United Arab Emirates
Background: Multiple sclerosis (MS) is a disabling life-long dis-
ease that manifests in different ways. Its associated costs and its 
economic impacts on young individuals have not been fully eval-
uated in the Middle East and North Africa (MENA) region. 
Various studies have been conducted globally to determine the 
causes, incidence, associated risk factors, and costs and its effect 
on people afflicted with MS.
Methods: A total of 109 patients with MS attending Mafraq 
Neurology clinic were involved in the study after approval from 
the Mafraq Research Ethics Committee. Data were collected ret-
rospectively from the CERNER patient data base. Data included 
outpatient clinic visits, medications, hospital admissions, emer-
gency department visits, magnetic resonance imaging (MRI) 
brain and spine, laboratory tests including (complete blood count 
(CBC), liver function tests (LFTs), vitamin D) from 2010 to 2017, 
and sick leaves for the year 2016.
Results: Patient’s age ranged from 16 to 64 years with a mean of 
34 years. A total of 26 nationalities were represented. Data were 
collected between 2010 and 2017 reporting on eight services. The 
mean cost for outpatient services was 683 AED. The mean cost for 
hospital admission was 131,265 AED. The mean cost for emer-
gency visits was 704 AED. Brain MRIs had a mean of 1235 AED 
while spine MRIs had a mean cost of 1163 AED. The mean cost of 
medications was 93,980 AED. In 2016, the sick leaves had a mean 
cost of 7958 AED.
Conclusion: Our research shows that the management of patients 
with MS is highly costly, and this cost can even increase with time 
leading to a real economic burden. Further studies are needed to 
identify a solid plan to decrease the burden of this disease.
2
Practice of complementary and alternative medicine (CAM) 
among patients with multiple sclerosis in Eastern Region, 
Saudi Arabia
Erum Mubbashir Shariff, Ali Malik AlAhmed, Alaa Al-Majed, 
Majed AbdAli, Fahd Al-Khamis, Sadiq Al-Salman and Foziah 
Al-Shammrani
King Fahd University Hospital, Imam Abdulrahman Bin Faisal 
University, Al-Khobar, Saudi Arabia
Background: Little is known about the prevalence and practice of 
complementary and alternative medicine (CAM) among patients 
with multiple sclerosis (MS) in the Arab world. Studying CAM in 
Saudi population is important as it will reflect the influence of 
psychosocial, cultural, and religious factors on health beliefs and 
behaviors.
Objectives: The aim of this study was to determine knowledge 
and attitudes about CAM, prevalence of its use, reasons for its use, 
and types of CAM used in patients with MS in eastern province of 
Saudi Arabia.
Methods: This was a cross-sectional hospital-based study 
conducted in the MS clinic of King Fahd Hospital, Imam 
Abdulrahman Bin Faisal University. After obtaining informed 
consent to participate in the study, patients with MS were required 
to complete a questionnaire. Questionnaire includes questions 
divided into three categories: (1) demographic information, (2) 
specific characteristics of patient’s disease, and (3) non-disease 
modifying drug (DMD) therapies used by patients (dietary inter-
ventions, such as vitamins and minerals, and special dietary pattern 
(i.e. goat milk, salt free, fat free) used for >3 months at least).
Results: A total of 100 patients from the MS clinic in King Fahd 
Hospital completed the survey. Of 100 patients, males were 35%, 
and females were 65%. Majority of patients were Saudi national 
(92%). Of 100, 4% were illiterate, 2% could read and write, 4% 
have primary education, 23% had secondary education, 54% were 
graduate, and 13% have completed post-graduation. Basic occu-
pation was job in 51%, while 20% were jobless. Commonly used 
DMDs were interferon beta 1a in 68% of patients. Almost half of 
the patients had more than attacks in the past year (47%). Majority 
of patients had history of CAM use (99%), and the main reason to 
use CAM was a feeling of participation in management in 43%, 
followed by successful stories from other patients in 28%, getting 
recommendations from others in 17%, and 12% felt that DMDs 
are not working properly. The most common CAM was prayers in 
34%, followed by dietary medicines in the form of vitamins, min-
erals, and special dietary patterns in 27%, Hejama in 20%, and 
mind–body medicine in 17%. Majority of patients (52%) got the 
knowledge of CAM through social media.
Conclusion: CAM treatments were largely used by patients with 
MS in eastern province of Saudi Arabia. In view of the common 
belief that CAM has fewer side effects than conventional medi-
cine, neurologists need to increase their awareness of CAM.
3
Developing multiple sclerosis in Bernard–Soulier syndrome 
patient
Reguig Abdelhamid, Barka Bedrane Zahira, Allal Salim, Saadi 
Khadidja, Louhibi Cherifa, Boudjelal Moad, Merad Atif, 
Dendane Oussama and Bouchenak Khelladi
Neurology Department, University Hospital of Tlemcen, 
Tlemcen, Algeria
Background: Bernard-–Soulier syndrome (B-SS) is a rare inher-
ited bleeding disorder caused by abnormal platelets and subse-
quent abnormal clotting.
Methods: We report on a patient diagnosed with multiple sclero-
sis (MS) and B-SS.
Results: A 36-year-old female was admitted to our hospital com-
plaining of gait unsteadiness and imbalance and slurred speech. 
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She was diagnosed with B-SS 11 years prior to presentation. Her 
brain magnetic resonance imaging (MRI) revealed hyperintense 
lesions in the cerebellar peduncle, periventricular demyelinating 
lesions in T2, and fluid attenuated inversion recovery (FLAIR) 
suggestive of MS Moreover, her cervical MRI revealed one 
hyperintense demyelinating lesion. Her lumbar puncture showed 
positive oligoclonal bands. She was diagnosed with secondary 
progressive MS.
Conclusion: Coexistence of the two diseases has not yet been 
described in the literature. Further studies are needed to clarify 
this issue.
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Vitamin D and multiple sclerosis in a cohort of Algerian 
patient
Barka Bedrane Zahira, Allal Salim, Saadi Khadija, Reguig 
Abdelhamid, Louhibi Cherifa, Boudjelal Moad, Merad Atif, 
Dendene Oussama and Bouchenak Khelladi Djaoued
Neurology Department, University Hospital of Tlemcen, 
Tlemcen, Algeria
Background: The risk of multiple sclerosis (MS) is determined 
by genetic and environmental factors. One of the latter is vitamin 
D deficiency, which has attracted attention in the last decade. Our 
objective was to evaluate serum 25 hydroxyvitamin D (25-OH D) 
levels in patients with MS and determine whether this rate corre-
lated with the clinical characteristics of the disease.
Methods: We conducted a prospective study between January 
2016 and June 2017 during which serum 25-OH D levels were 
obtained from patients with MS. A serum level of 25-OH D 
>30 ng/mL was considered normal and a level between 30 and 
10 ng/mL was defined as vitamin D deficiency. Severe deficiency 
was defined at <10 ng/mL.
Results: In all, 143 patients with MS were included in the study. 
The serum level of vitamin D was collapsed in a high proportion 
of our patients (67%). There is no correlation between the 25-OH 
D level and the annualized rate of the previous year in patients 
with relapsing–remitting MS (RRMS). High Expanded Disability 
Status Scale (EDSS) scores correlated with low vitamin D levels.
Conclusion: Any hypovitaminosis D should be corrected in 
patients with MS, and long-term evaluation is necessary in order 
to assess the impact of this supplementation on long-term disease 
progression.
5
Pediatric multiple sclerosis in a cohort of Algerian patient
Barka Bedrane Zahira, Allal Salim, Saadi Khadija, Reguig 
Abdelhamid, Louhibi Cherifa, Boudjelal Moad, Dendene 
Oussama, Merad Atif and Bouchenak Khelladi Djaoued
Neurology Department, University Hospital of Tlemcen, 
Tlemcen, Algeria
Background: Multiple sclerosis (MS) is a disease of young 
adults, but its onset in childhood is frequently observed. Recently, 
several networks are collaborating to advance the management of 
this disease in the pediatric population.
Objectives: To describe the clinical and paraclinical characteris-
tics of a pediatric MS population; to assess the response to differ-
ent treatments; and to describe the evolution of the disease.
Methods: This is a retrospective study of patients aged less than 
18 years who were diagnosed with MS according to 2010 
McDonald’s criteria.
Results: In all, 25 pediatric MS patients were included. The mean 
age was 15 ± 4.38 years. Most of the patients (76.6%) had a mono 
symptomatic onset. Baseline brain magnetic resonance imaging 
(MRI) showed periventricular lesions in 91% of the patients and 
cerebellum and corpus callosum lesions in 38% and 36% of the 
cases, respectively. A total of 87.5% of the patients were diag-
nosed with relapsing–remitting MS. About 76% of the patients 
were treated with interferons while 9.5% were maintained on 
monthly natalizumab infusion. Their baseline Expanded Disability 
Status Scale (EDSS) ranged between 4 and 6 in 28.5% of the 
patients and greater than 6 in 19%. The median time to reach 
EDSS 6 in our cohort was 8.27–10.68 years compared to 12.17–
13.24 years in the adult population.
Conclusion: In pediatric MS, functional and cognitive dysfunction 
can interfere with academic achievement. Early treatment is highly 
recommended to improve the quality of life of young patients.
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Body size and the risk of multiple sclerosis in Saudi Arabia, 
case–control study, 2016
Osama Al Wutayd1, Ashry G Mohammad2, Jameela Saeedi3, 
Hessa Alotaibi4 and Mohammad Al Jumah5,6
1Unaizah College of Medicine, Qassim University, Unaizah, Saudi 
Arabia; 2King Khalid University Hospital, Riyadh, Saudi Arabia; 
3King Abdullah Bin Abdulaziz University Hospital, Princess 
Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; 
4King Fahad General Hospital, Ministry of Health, Jeddah, Saudi 
Arabia; 5KAIMRC, King Saud bin Abdulaziz University for Health 
Sciences, Riyadh, Saudi Arabia; 6King Fahad Medical City, 
Riyadh, Saudi Arabia
Background: Overweight/obesity may increase risk of multiple 
sclerosis (MS).
Objective: To determine whether body size during different age 
periods is associated with an increase in MS risk in Saudi Arabia.
Methods: In all, 307 MS cases and 307 healthy controls were 
selected from MS clinics and wards in three main cities in different 
regions in KSA. Participants selected their body size by choosing a 
silhouette 1–9 during different age periods. Odds ratio (OR) and 
95% confidence intervals (CIs) were calculated. Logistic regression 
models were adjusted for potential confounding factors.
Results: A large body size 6–9 and body size 5 during intermediate 
school level increase risk of MS (adjusted OR (AOR): 3.74, 95% 
CI: 1.39–10.04 and AOR: 2.41, 95% CI: 1.01–5.75, respectively), 
while being with smallest body size (1) during intermediate school 
decreases risk of MS (AOR: 0.28, 95% CI: 0.13–0.61).
Conclusion: Overweight and obesity during intermediate school 
level were associated with increased risk of MS.
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Environmental exposures and the risk of multiple sclerosis 
(MS) in Saudi Arabia (KSA), 2016
Osamah Al Wutayd1, Ahmed G Mohamed2, Jamelah Saeedi3, 
Hessah Alotaibi4 and Mohammed Aljumah5,6
1Unaizah College of Medicine, Qassim University, Unaizah, 
KSA; 2King Fahad Medical City, Riyadh, KSA; 3Princess Nourah 
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bint Abdulrahman University, Riyadh, KSA; 4King Fahad 
General Hospital, Jeddah, KSA; 5KAIMRC, King Saud bin 
Abdulaziz University for Health Sciences, Riyadh, KSA; 6King 
Khalid University Hospital, Riyadh, KSA
Background: Multiple sclerosis (MS) is one of the disabling 
chronic diseases affecting adults. The risk factors are not yet 
known in KSA, while the prevalence of MS is rising. The goal of 
the study was to determine the association between environmental 
exposures among patients with MS.
Methods: In all, 307 MS cases and 307 healthy controls were 
selected from MS clinics and wards in three main cities. 
Information on demographics, family history of MS, medical and 
family history, sun exposure, obesity at different age periods, 
tobacco use, diets, consanguinity role, and coffee consumption 
was obtained from self administered questionnaire (SAQ).
Logistic regression (LR) models were adjusted for potential 
confounding factors.
Results: Mean age was 33 years and 76% were female. The multi-
variate (MV) analysis showed that being the first birth order position 
(odds ratio (OR): 1.79; 95% confidence interval (CI): 1.11–2.88), 
having measles (OR: 3.11; 95% CI: 1.76–5.5), having a large body 
size at primary school level (OR: 4.35; 95% CI: 1.20–15.84), eating 
from restaurant ≥5 times/week (OR: 2.14; 95% CI: 1.11–4.13), and 
having a family history of MS (OR: 6.25; 95% CI: 3.09–12.62) were 
independently associated with increased risk of MS. Eating ≥5 serv-
ings of fruit/week (OR: 0.31; 95% CI: 0.20–0.47), having a high sun 
exposure at primary school level (OR: 0.58; 95% CI: 0.37–0.91), 
and also having a high sun exposure at university school level (OR: 
0.50; 95% CI: 0.30–0.84) were independently associated with 
decreased risk of MS.
Conclusion: Our study suggests a protective role of high sun expo-
sure and consumption of fruits during primary and university school 
levels. Obesity during primary school level is associated with 
increased risk of MS. Encouragement of outdoor activity and healthy 
diet at school level especially for females is highly suggested.
8
Cardiovascular abnormalities in patients with relapsing–
remitting multiple sclerosis
Lobna Ahmed Talaat El-Ghoneimy, Nevin Shalaby, Alaa 
Elmazny, Yasser El-Baghdady and Hatem Shehata
Kasr Al Ainy-Cairo University, Cairo, Egypt
Background: Autonomic dysfunction is a prevalent but fre-
quently overlooked symptom among patients with multiple scle-
rosis (MS). It can be explained by lesions within central nervous 
system (CNS) involving areas responsible for autonomic regula-
tion. Impairment of cardiovascular (CV) autonomic reflexes has 
been described in multiple sclerosis (MS), and believed reflecting 
dysfunction of reflex pathways located within the CNS. Our 
objectives were to detect the cardiovascular disturbances in 
patients with relapsing–remitting MS (RRMS) and to correlate the 
location of the brain lesions with such disturbances.
Methods: Forty-eight patients with RRMS, according to revised 
McDonald’s criteria (2010), and 25 healthy control subjects were 
included. Evaluation of the CV functions in both groups was car-
ried out via symptom analysis, assessment of blood pressure (BP) 
in response to change in posture, electrophysiological studies for 
heart rate variability (HRV) testing using 24-hour HR recording 
by halter electrocardiography (ECG), and R-R interval variation 
in response to normal and deep breathing, valsalva maneuver, and 
standing.
Results: Postural hypotension was reported in 41% of patients with 
RRMS, having both symptoms of orthostatic dizziness and decrease 
in systolic BP (SBP) and/or diastolic BP with a mean of 
25 ± 11 mmHg for SBP and 10 ± 4 mmHg for diastolic BP. Changes 
in heart rate after deep breathing were evident in 54.3% which 
showed an increase or decrease in HR of less than 10 beats/min 
with significant difference when compared to controls (p = 0.04). 
Whereas no significant difference was found in the R-R interval 
variability test between patients and controls with normal breathing, 
valsalva maneuver, and standing up (p = 0.17; 29; 0.39 respec-
tively). Patients having pericallosal plaques had a significant differ-
ence in the mean change in SBP on standing compared to those 
without such lesions (p = 0.04). However, no significant correlation 
was detected between the CV symptoms and the duration of the 
disease, total number of relapses, or the disability progression.
Conclusion: Autonomic dysfunction is not uncommon in patients 
with RRMS including CV reflexes’ dysfunction which should be 
identified to allow proper symptomatic management.
9
Epidemiological data of patients with multiple sclerosis
Ana Maria Canzonieri, Thais Mira Simandi and Dyana Gervana 
de Oliveira Fernandes
Brazilian Association of Multiple Sclerosis (ABEM), Sao Paulo, 
Brazil
Background: Multiple sclerosis (MS) is a demyelinating disease 
of the central nervous system, of undefined etiology, so epidemio-
logical studies are fundamental.
Objectives: To portray epidemiological characteristics in patients 
with MS.
Methods: Data collection of 600 epidemiological questionnaires 
sent by mail, by a Civil Social Institution, in São Paulo, Brazil, to 
patients with MS.
Results: A total of 177 people were randomly selected from a 
sample of 600 patients with MS between 2006 and 2010. A total 
of 65% of them were from São Paulo, 70% were women, 55% 
were married, 76% were white, and 41% had a high school 
diploma and 40% had a university diploma. The majority of them 
were born in the 1970s, with the oldest being born in 1938 and the 
youngest in 1997. Only 24% were working. As for the symptoms, 
66% of the patients presented with muscle weakness, 57% with 
fatigue, 79% with numbness, and 56% with imbalance. The psy-
chiatric symptoms observed were mood disorders in 51% of the 
cohort. Most of the patients performed cervico-dorsal and brain 
magnetic resonance imaging (MRI) and 55% of them were main-
tained on interferon.
Conclusion: The majority of our cohort were predominately 
female who were born in 1970s. Most of them are not working 
due to physical and psychological symptoms.
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Quality-of-life evaluation with MSQOL-54, of patients with 
multiple sclerosis
Ana Maria Canzonieri, Thais Mira Simandi, Giulianna Mendes 
Ferrero and Roger Pereira Silva
Brazilian Association of Multiple Sclerosis (ABEM), Sao Paulo, 
Brazil
NP4 MENACTRIMS Abstracts 
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Background: Multiple sclerosis (MS) is a degenerative and 
chronic disease that causes physical and cognitive disorders lead-
ing to changes in quality of life.
Objectives: To evaluate patient’s perception of his physical and 
mental quality of life.
Methods: Patients with MS were evaluated, through MSQOL-54, 
in Civil Social Institution, in São Paulo, Brazil.
Results: A total of 35 people (11 men and 24 women) were 
assessed. The predominant age group was between 40 and 
60 years (63.1%) with a mean age of 44.49 years and standard 
deviation (SD) of 11.34 years; 42.9% were married; 21% were 
retired and unemployed; and 74.3% had a high level of education. 
A total of 40% were diagnosed 10–20 years ago: 82.9% had 
relapsing–remitting MS (RRMS); 74.3% had an Expanded 
Disability Status Scale (EDSS) up to 3.5; 94.3% had at least one 
relapse and 65.2% had no relapses in the last 2 years. About 91.4% 
received treatment; 28.6% were maintained on interferon therapy 
and 40% were taking vitamin D supplement in addition to their 
disease-modifying therapy. A total of 62.9% complained of motor 
problems but did not use assistive devices for ambulation; 74.3% 
had visual problems and 28.6% suffered from cognitive problems 
mainly attention disorder; 40% had urinary problems; and 22.9% 
complained of insomnia. As for fatigue, 54.3% had mental fatigue, 
88.6% physical fatigue and 45.7% visual fatigue. About 84.1% 
scored above average in general health perception (mean 63.36) 
and 75.4% were above average in mental health (mean 55.98) in 
MSQOL-54.
Conclusion: We concluded that the perception about the physical 
and mental quality of life is above average, with the perception of 
physical health being greater than that of mental health.
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Long-term lymphocyte counts in patients with RRMS treated 
with cladribine tablets
Per Soelberg-Sorensen1, Fernando Dangond2, Christine Hicking3 
and Gavin Giovannoni4
1Danish Multiple Sclerosis Center, Department of Neurology, 
University of Copenhagen Rigshospitalet, Copenhagen, 
Denmark; 2EMD Serono, Inc., Billerica, MA, USA; 3Merck 
KGaA, Darmstadt, Germany; 4Blizard Institute, Barts and 
The London School of Medicine and Dentistry, Queen Mary 
University of London, London, UK
Background: Cladribine tablets’ (CTs) efficacy was demon-
strated in the CLARITY study. Lymphopenia was the most com-
monly reported adverse event (AE), consistent with CT’s 
mechanism of action. Absolute lymphocyte counts (ALCs) were 
investigated to 312 weeks and B- and T-cell subsets to 240 weeks 
after the first administered CT dose, in patients with relapsing–
remitting MS (RRMS) receiving two annual courses of CT 
(3.5 mg/kg cumulative dose) followed by no further active 
treatment.
Methods: Data from patients randomized to CT in CLARITY/
CLARITY Extension including time in the PREMIERE registry 
(N = 685) were pooled. Median cell counts are reported.
Results: Baseline ALC was 1.86 × 109/L. During Year (Y)1, ALC 
reached nadir at Week (Wk) 9 (1.00 × 109/L) and then gradually 
increased. During Y2, ALC reached nadir at Wk55 (0.81 × 109/L) 
and recovered to normal (≥1.00 × 109/L) by the end of Y2 (Wk96), 
continuing to increase thereafter. ALC returned to normal in 75% 
of patients by Wk144. Baseline CD4+ was 851 cells/µL. After 
treatment in Y1, CD4+ reached nadir at Wk16 (385 cells/µL) and 
then gradually increased. CD4+ reached nadir after Y2 treatment 
at Wk60 (292 cells/µL). Values reached the 350 cells/µL threshold 
by approximately Wk120, continuing to improve thereafter. 
Baseline CD8+ was 378 cells/µL. CD8+ reached Y1 nadir at 
Wk16 (239 cells/µL) and then gradually increased; Y2 nadir was 
reached at Wk72 (232 cells/µL). CD8+ recovered quickly after 
treatment and never decreased below the 200 cells/µL threshold. 
Baseline CD19+ was 205 cells/µL. After Y1 treatment, CD19+ 
reached nadir at Wk9 (18 cells/µL) and after Y2 treatment at 
Wk52 (31 cells/µL). CD19+ then gradually recovered, reaching 
the 100 cells/µL threshold by Wk96, continuing to improve 
thereafter.
Conclusion: Lymphocyte recovery begins soon after CT treat-
ment, with ALC, CD19+ B cells and CD4+ T cells reaching 
threshold values by 7.5, 12 and 18 months, respectively, after the 
last dose in Y2. CD8+ cells never decreased below the threshold.
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Analysis of relapse rates and relapse-free patients in the 
CLARITY and CLARITY Extension studies
Gavin Giovannoni1, Giancarlo Comi2, Stuart Cook3, Kottil 
Rammohan4, Peter Rieckmann5, Per Soelberg-Sorensen6, Patrick 
Vermersch7, Christine Hicking8, Abidemi Adeniji9 and Fernando 
Dangond9
1Blizard Institute, Barts and The London School of Medicine 
and Dentistry, Queen Mary University of London, London, 
UK; 2Department of Neurology and Institute of Experimental 
Neurology, Università Vita-Salute San Raffaele, Ospedale San 
Raffaele, Milan, Italy; 3New Jersey Medical School, Rutgers, 
The State University of New Jersey, Newark, NJ, USA; 4MS 
Research Center, Department of Neurology, Miller School of 
Medicine, University of Miami, Miami, FL, USA; 5Department 
of Neurology, Hospital for Nervous Diseases, Medical Park 
Loipl and University of Erlangen, Bischofswiesen, Germany; 
6Danish Multiple Sclerosis Center, Department of Neurology, 
Copenhagen University Hospital Rigshospitalet, Copenhagen, 
Denmark; 7Université Lille, CHRU de Lille, LIRIC-INSERM 
U995, Lille, France; 8Merck KGaA, Darmstadt, Germany; 
9EMD Serono, Inc., Billerica, MA, USA
Background: In CLARITY, giving cladribine tablet (CT) annu-
ally for 2 years significantly reduced relapse rates and disability 
progression versus placebo (PBO). Here, the efficacy of 2 year’s 
additional treatment with CTs or PBO in patients with relapsing 
multiple sclerosis (RMS) was assessed in an extension (EXT) to 
the CLARITY study.
Methods: In CLARITY-EXT, patients who had received PBO in 
CLARITY were assigned to CT 3.5 mg/kg body weight; those 
who received CT (3.5 or 5.25 mg/kg) in CLARITY were re-ran-
domised (2:1) to CT 3.5 mg/kg or PBO. Annualised relapse rates 
(ARRs) and proportions of patients qualifying relapse free were 
compared at different times (i.e. CLARITY and CLARITY-EXT) 
within the following groups: patients treated with CT 3.5 mg/kg in 
CLARITY and PBO in CLARITY-EXT (n = 98); CT 3.5 mg/kg in 
CLARITY and CT 3.5 mg/kg in CLARITY-EXT (n = 186); CT 
5.25 mg/kg in CLARITY and CT 3.5 mg/kg in CLARITY-EXT 
(n = 186); PBO in CLARITY and CT 3.5 mg/kg in CLARITY-
EXT (n = 244).
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Results: No significant differences in ARR were seen between 
CLARITY and CLARITY-EXT except in patients who received 
PBO in CLARITY and CT 3.5 mg/kg in CLARITY-EXT (0.26 vs 
0.10, p < 0.0001). In CLARITY-EXT, >70% of patients qualified 
relapse free in each group with no significant differences seen 
between CLARITY and CLARITY-EXT except in patients treated 
with PBO in CLARITY and CT 3.5 mg/kg in CLARITY-EXT 
(58.0% vs 79.6%, p < 0.0001).
Conclusion: Comparing CLARITY with CLARITY-EXT dem-
onstrates that CT produced durable clinical benefits: patients who 
received CT in CLARITY and PBO in CLARITY-EXT main-
tained low relapse rates throughout. Patients who received CT in 
CLARITY and CT in CLARITY-EXT showed no additional ben-
efit versus CT treatment in CLARITY only. For patients who 
received PBO in CLARITY, switching to CT in CLARITY-EXT 
significantly reduced ARR and increased the proportion of 
relapse-free patients.
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Cladribine tablets in the ORACLE-MS study open-label 
maintenance period: Analysis of efficacy in patients after 
conversion to clinically definite multiple sclerosis (CDMS)
Giancarlo Comi1, Thomas Leist2, Mark S Freedman3, Bruce 
AC Cree4, Patricia K Coyle5, Hans-Peter Hartung6, Patrick 
Vermersch7, Doris Damian8 and Fernando Dangond8
1Department of Neurology and Institute of Experimental 
Neurology, Università Vita-Salute San Raffaele, Ospedale San 
Raffaele, Milan, Italy; 2Division of Clinical Neuroimmunology, 
Jefferson Medical College, Thomas Jefferson University, 
Philadelphia, PA, USA; 3Department of Medicine, University 
of Ottawa and the Ottawa Hospital Research Institute, 
Ottawa, ON, Canada; 4UCSF Multiple Sclerosis Center, San 
Francisco, CA, USA; 5Department of Neurology, Stony Brook 
University, Stony Brook, NY, USA; 6Department of Neurology, 
Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 
7Department of Neurology, Université Lille, CHRU Lille, 
LIRIC-INSERM U995, Lille, France; 8EMD Serono, Inc., 
Billerica, MA, USA
Background: In the ORACLE-MS study in patients with a first 
demyelinating attack, cladribine tablets (CTs; 3.5 and 5.25 mg/kg) 
significantly reduced the risk of conversion to clinically definite 
multiple sclerosis (CDMS) compared with placebo. If CDMS 
occurred in the double-blind, initial treatment period (ITP), 
patients were treated with subcutaneous (SC) interferon-beta-1a 
in an open-label maintenance period (OLMP).
Methods: Participation in the ORACLE-MS OLMP was depend-
ent on the clinical course of the patient’s disease in the ITP. 
Patients in ORACLE-MS who converted to CDMS during the ITP 
entered the OLMP and were treated with SC interferon-beta-1a 
(titrated over 4 weeks up to the dose of 44 µg) administered three 
times per week. Annualised relapse rate (ARR) was assessed dur-
ing ORACLE-MS OLMP, in patients randomised to CTs 3.5 and 
5.25 mg/kg, or placebo, in the ITP.
Results: In all, 109 patients in ORACLE-MS converted to CDMS 
in ITP and received at least one dose of interferon-beta-1a. The 
median time on interferon-beta-1a was 56.0 weeks. Estimated 
ARRs in the OLMP were 0.14 (95% confidence interval (CI): 
0.00–0.27) for patients (n = 25) originally treated with CT 3.5 mg/
kg; 0.24 (95% CI: 0.07–0.40) for patients (n = 24) originally 
treated with CT 5.25 mg/kg and 0.42 (95% CI: 0.28–0.56) for 
patients (n = 60) who originally received placebo in the ITP.
Conclusion: A treatment effect versus placebo of CTs given in 
ITP continues to be observed in patients who convert to CDMS 
and switch to treatment with SC interferon-beta-1a. Patients who 
had been treated with CTs and who had converted to MS during 
ORACLE-MS ITP had lower ARR during the OLMP, relative to 
those patients who had received placebo during ORACLE-MS 
ITP.
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Cladribine tablets for treatment of patients with multiple 
sclerosis (MS): Integrated analysis of safety from the MS 
clinical development program
Stuart Cook1, Thomas Leist2, Giancarlo Comi3, Xavier 
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Background: The efficacy of cladribine tablets (CTs) for early 
multiple sclerosis and relapsing MS (RMS) has been shown in 
ORACLE-MS, CLARITY, and CLARITY Extension. Adverse 
events (AEs) from these studies have been reported separately. 
Here, we report a pooled integrated safety analysis of CT’s AE 
profile from trials which evaluated CT 3.5 mg/kg (CT3.5) as mon-
otherapy in patients with early MS or RMS.
Methods: The CT3.5 cohort comprised 923 patients (3432.65 
patient-years (PY) exposure) derived from CLARITY, CLARITY 
Extension, ORACLE-MS, and the PREMIERE registry; the pla-
cebo cohort comprised 641 patients (2025.97 PY).
Results: The mean study period for patients receiving CT3.5 was 
194 weeks and 165 weeks for placebo recipients. Adjusted AE 
(Adj-AE) per 100 PY rates for CT3.5 and placebo, respectively, 
were treatment emergent AE (TEAE), 103.3 and 94.3; TEAEs 
leading to discontinuation, 2.1 and 1.1; serious AEs, 4.0 and 3.6; 
serious AEs leading to death, 0.26 and 0.25. Regarding known 
events expected with CT treatment, Adj-AE per 100 PY for lym-
phopenia were 7.94 (CT3.5) and 1.06 (placebo); for system organ 
class of infection and infestations, 24.93 (CT3.5) and 27.05 (pla-
cebo); herpes zoster, 0.83 (CT3.5) and 0.20 (placebo). Adj-AE per 
100 PY for the system organ class of neoplasms, benign, malig-
nant, and unspecified was 1.14 and 1.01, for CT3.5 and placebo, 
respectively.
Conclusion: The AE profile for CT3.5 as monotherapy has been 
well-characterized in a pooled population of patients with early 
MS and active RMS. Lymphopenia was expected from CTs’ mode 
of action; herpes zoster was reported more frequently in patients 
experiencing Grade 3 or 4 lymphopenia; no clustering of types of 
malignancy was seen, and no malignancies commonly associated 
with immunosuppression were observed.
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Efficacy of cladribine tablets 3.5 mg/kg in high disease 
activity (HDA) subgroups of patients with relapsing multiple 
sclerosis (RMS) in the CLARITY study
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Background: In the CLARITY study, treatment with cladribine 
tablets (CTs) showed strong efficacy versus placebo in a large 
cohort of patients with relapsing multiple sclerosis (RMS) over 
2 years. Patients with high disease activity (had) are at higher 
risk of relapses and disability progression. Here, the effects of 
CT 3.5 mg/kg (CT3.5) versus placebo were compared in sub-
groups of CLARITY patients selected using two HDA 
definitions.
Methods: CLARITY patients randomised to CT3.5 (N = 433) or 
placebo (N = 437) were retrospectively analysed using two differ-
ent HDA definitions based on relapse history, prior treatment and 
magnetic resonance imaging (MRI) characteristics. Patients were 
categorised according to whether they had experienced high 
relapse activity (HRA; ≥2 relapses in the previous year) regardless 
of prior treatment, or HRA plus treatment nonresponse 
(HRA + TNR; ≥2 relapses in the previous year, or ≥1 relapse in 
previous year while on disease modifying drug (DMD) therapy 
and ≥1 T1 Gd+ or ≥9 T2 lesions).
Results: In the overall CLARITY population, CT3.5 reduced the 
risk of 6-month confirmed Expanded Disability Status Scale 
(EDSS) progression versus placebo (hazards ratio (HR) = 0.53, 
95% CI: 0.36–0.79). A larger risk reduction for CT3.5 versus pla-
cebo was seen (HR = 0.18 each, 95% CI: 0.08–0.44 and 0.07–
0.43) in the HRA subgroup (p = 0.0036 nominal significance vs 
non-HRA) and the HRA + TNR subgroup (p = 0.0037 signifi-
cance vs non-HRA+TNR), indicating greater responsiveness to 
CT3.5 in patients identified by these criteria. Similar patterns 
were observed for time to 3-month EDSS progression. ARR was 
lower with CT3.5 than placebo in the overall population (relative 
risk (RR) = 0.42, 95% CI: 0.33–0.52), and even lower with HRA 
(RR = 0.32, 95% CI: 0.22–0.47) and HRA + TNR (RR = 0.33, 
95% CI: 0.23–0.48; each p < 0.0001 vs placebo). Strong treatment 
effects on radiological markers were observed in each HDA 
subgroup.
Conclusion: In CLARITY, patients identified by HDA criteria 
showed clinical and MRI responses to CT3.5 that were generally 
better than, or at least comparable with, the overall CLARITY 
population.
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in patients with early and relapsing multiple sclerosis 
(ORACLE-MS, CLARITY and CLARITY extension)
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Background: Efficacy of cladribine tablets (CTs) was demon-
strated in patients with early multiple sclerosis (MS) 
(ORACLE-MS) and relapsing–remitting MS (RRMS) (CLARITY/
Extension). We evaluate the effect on B, T and natural killer (NK) 
cell profiles after CT administration.
Methods: Longitudinal evaluation of peripheral blood lympho-
cyte subtypes was conducted for patients receiving the first course 
of CT either from the initial 3.5 mg/kg active treatment groups 
(ORACLE-MS and CLARITY) or the placebo-switched-to-
active-treatment groups (CLARITY Extension). Lymphocytes 
were immunophenotyped at baseline and Weeks 5, 13, 24 and 48. 
Changes in cell numbers and composition of lymphocyte subtypes 
were evaluated.
Results: Temporal profiles of CD19+ B lymphocytes and CD4+ 
and CD8+ T lymphocytes were generally consistent across stud-
ies. The fastest cell reduction occurred with CD19+ B cells 
(approximately 75% at Week 5 in each study). CD19+ B-cell 
nadir occurred at Week 13 with 81%, 84% and 82% median reduc-
tions for patients receiving CT in CLARITY (N = 97), CLARITY 
Extension (N = 136) and ORACLE-MS (N = 41), respectively. 
Reconstitution of CD19+ B cells towards baseline occurred from 
Week 24 to 48. CD4+ and CD8+ T cells were also markedly 
reduced, but less than CD19+ B cells (at most 55% at Week 13 for 
CD4+ cells and 48% at Week 48 for CD8+ cells in patients treated 
with CT in ORACLE-MS). Reductions in T cells were discontinu-
ous but had not fully returned to baseline by Week 48. CD16+/
CD56+ NK cells were also transiently reduced; nadir occurred at 
Week 13 in ORACLE-MS (44% reduction), with recovery at 
Weeks 24 (29% reduction) and 48 (23% reduction).
Conclusion: CT achieved an early and discontinuous reduction in 
B cells with rapid reconstitution to baseline, and a moderate and 
discontinuous reduction in T cells. There were early decreases in 
NK cells followed by rapid recovery.
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Background: Cladribine tablets (CTs), given annually for 2 years 
in short-duration courses in CLARITY, significantly improved 
clinical (relapses and disability progression) and magnetic reso-
nance imaging (MRI) outcomes. After a variable treatment gap 
(median 40 weeks), 2 additional years of CT treatment versus pla-
cebo were assessed in CLARITY-Extension (EXT). This analysis 
assessed the efficacy of CT in patients with relapsing–remitting 
multiple sclerosis (RRMS) treated for 2 additional years beyond 
the initial 2 years (CLARITY).
Methods: In CLARITY, patients were randomized to treatment with 
placebo or CT (3.5 or 5.25 mg/kg bodyweight). In CLARITY-EXT, 
placebo recipients in CLARITY received CT3.5 mg/kg; cladribine 
recipients were re-randomized 2:1 to CT3.5 mg/kg or placebo (five 
groups in total). This allowed comparison of 2 years-only treatment 
plus ≥2 years follow-up versus 4 years’ treatment. Clinical assess-
ments included annualized relapse rate (ARR) and disability score.
Results: Baseline characteristics were similar across groups, 
although placebo recipients in CLARITY showed evidence of 
greater clinical and magnetic resonance imaging (MRI) disease 
activity. In groups treated with CT in CLARITY, efficacy was 
maintained in CLARITY-EXT; 2 years’ additional CT treatment 
was associated with a slight incremental benefit. ARR in patients 
treated with CT3.5 mg/kg in CLARITY and placebo in CLARITY-
EXT was 0.15 (97.5% confidence interval (CI): 0.09–0.21; n = 98); 
in patients treated with CT3.5 mg/kg in both CLARITY and 
CLARITY-EXT, ARR was 0.10 (97.5% CI: 0.06–0.13; n = 186, 
p = 0.059). Both groups showed comparable proportions of 
relapse-free patients (75.6% and 81.2%, respectively) and time-to-
first relapse (vs first dose in CLARITY). Median Expanded 
Disability Status Scale (EDSS) scores were comparable across all 
groups; no significant between-group differences were seen in 
time to confirmed 3-month EDSS progression in CLARITY-EXT.
Conclusion: CLARITY-EXT demonstrated that in a majority of 
patients, the clinical benefits of CT3.5 mg/kg given in Years 1 and 
2 may be maintained for ≥4 years, with decisions on further treat-
ment based on monitoring during this period.
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If initial repeated neuromyelitis optica antibody is negative, 
do we still consider neuromyelitis optica spectrum disorder?
Mona Chetan Thakre
Al Zahra Hospital Dubai, Dubai, United Arab Emirates
Background: To present a case of long extensive transverse mye-
litis and postrema syndrome with a persistent negative 
neuromyelitis optica (NMO) antibody for 2 years which later 
became positive.
Case history: This is the case of a 40-year-old Indian lady who 
presented with history of acute progressive paraparesis in May 
2015. Her cervico-dorsal magnetic resonance imaging (MRI) 
showed a long extensive demyelinating lesion at the level of 
T2–T10. She received a pulse of methylprednisolone for 5 days 
but she did not improve. Therefore, she underwent five sessions 
of plasmapheresis. Her lumbar puncture showed a high white 
blood cell (WBC) 166, cerebrospinal fluid (CSF) protein of 
1.2 g/dL, and positive oligoclonal bands. Cytology and acid-
fast bacillus (AFB) polymerase chain reaction (PCR) were neg-
ative. Anti-nuclear antibody (ANA) was 1:320. NMO antibody 
performed upon presentation and repeated after 6 weeks, 
3 months and 12 months was negative. Anti-myelin oligoden-
drocyte glycoprotein (MOG) antibody was also negative. She 
gradually improved and remained stable until February 2017 
when she experienced intractable vomiting. Her MRI showed a 
demyelinating lesion in the postrema region. She a pulse of 
methylprednisolone for 5 days after which she recovered well. 
She travelled to the United States and repeated her NMO anti-
body test there which became positive. She was started on ritux-
imab infusions every 6 months. Since then, she was clinically 
and radiologically stable on rituximab.
Conclusion: In typical NMO spectrum disorder (NMOSD), NMO 
antibody can still be negative initially. Corticosteroid treatment, 
plasmapheresis, or testing method could falsely affect the result. 
Thus, high clinical suspicion is required in NMOSD-suspected 
cases even when antibody is negative.
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Characterisation of novel anti-neuronal antibodies in 
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Faisal Ali Barnawi, Ariadna Fontes-Villalba and John Parratt
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Background: Grey matter pathology is extensive in relapsing–
remitting and secondary progressive multiple sclerosis (MS) and 
has been shown to correlate with disability. Histo-pathological 
studies demonstrate neuronal loss correlates strongly with reduc-
tion in cerebral volume. We previously identified novel anti-neu-
ronal antibodies in MS.
Objective: To describe the characteristics of novel anti-neuronal 
antibodies in MS.
Methods: In all, 79 patients with relapsing–remitting MS and 61 
healthy blood donors were analysed. Sera were applied to frozen 
cryostat sections of rat cortex, cerebellum, kidney and small intes-
tine that had been fixed using in vitro 2% paraformaldehyde per-
fusion. Bound IgG was detected using a goat anti-human IgG 
(Alexa Fluor 488) and M1 Zeiss Axiocam Imager. Specimens 
were analysed by two raters in a blinded fashion for binding to 
neurons and other central nervous system (CNS) structures and 
regarded as positive if fluorescence was greater than ++ which 
equivocated to an antibody dilution of more than 1:320.
Results: Anti-neuronal antibodies were more frequently detected 
in MS (35.4%, 28/79) than healthy controls (11.5%, 7/61, 
p < 0.05). Antibodies directed against neuronal cytoplasm were 
most frequent in MS (20.3%, 16/79) and usually involved cortical 
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neurons and cerebellar Purkinje cells although the pattern varied 
widely. An antibody directed against a vesicular intracytoplasmic 
component of interneurons (bipolar cells, Golgi, and basket cells) 
was found in 10.1% of patients with MS. Antibodies were also 
identified against synaptic vesicles, neurofilaments and neuronal 
nuclei.
Conclusion: Anti-neuronal antibodies are more frequent in MS 
than healthy people and have a wide distribution of targets. The 
heterogeneity of this response may imply epitope spreading and 
“bystander” immune responses although this needs further evalu-
ation for each of the numerous novel antibodies identified in this 
study.
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Background: Falls while walking are frequent in patients with 
multiple sclerosis (MS). The physical impacts of falls can cause 
activity limitations and may have significant effects on patient’s 
participation in the society. Therefore, an early gait stability index 
would be useful to identify patients at high risk of falling and to 
prevent the occurrence of future falls. Derived from chaos theory, 
local dynamic stability, defined by the maximal Lyapunov expo-
nent (LyE), assesses the sensitivity of a dynamic system to small 
perturbations and has been found to be associated with falling in 
the older adults. However, in patients with MS, this relationship 
has not been investigated previously. Therefore, the aim of this 
study was to prospectively investigate deficits in local dynamic 
stability as risk factors for falls in patients with MS.
Methods: Seventy patients with MS were assessed under two 
experimental conditions, including (1) normal walking and (2) 
normal walking with cognitive task (aloud backward counting). 
Kinematic data were collected using a seven-camera motion cap-
ture system while patients walked on a treadmill. A cluster of three 
infrared retro-reflective markers were placed over the level of T7 
to calculate local stability. Participants were classified as none-
fallers and fallers (≥1) based on their prospective fall occurrence.
Results: In this study, 42 (49%) participants recorded one or more 
falls and were classified as fallers. The results of logistic regres-
sion analysis revealed that LyE under both single (p < 0.01, odds 
ratio (OR) = 2.125 (1.230–3.671) and dual task (p < 0.05, 
OR = 1.689 (1.09–2.837)) conditions was able to significantly 
predict falls in patients with MS.
Conclusion: The results of this study can be used by clinicians to 
identify potential fallers in patients with MS. Moreover, assess-
ment of gait stability deficits and identification of more risk fac-
tors for falls in patients with MS can provide a background for 
development of perturbation-based rehabilitation programs for 
fall prevention.
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Anti-JCV antibody sero-positivity and index value among 
Iranian patients with multiple sclerosis and its correlation 
with demographic data and previous therapies
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Naser Moghadasi and Amir Reza Azimi
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Background: Anti-JC virus (JCV) antibody index is the predict-
ing factor of progressive multifocal leukoencephalopathy (PML) 
for patients with multiple sclerosis (MS) who are treated with 
natalizumab.
Methods: This cross-sectional study assessed all received anti-
JCV antibody test results of Iranian patients with MS between 
January 2014 and December 2016. Demographic data and disease 
characteristics were also obtained. After data quality control, sta-
tistical analysis was done using logistic regression.
Results: Among 803 patients with MS who were observed, the 
prevalence of anti-JCV antibody positivity was 67.9% (mean of 
index = 2.23; standard deviation (SD) = 1.16), and 67.6% of posi-
tive patients had index ≥1.5. Males were more anti-JCV antibody 
positive than females (81.7% and 64%, respectively; sig. <0.001, 
crude odds ratio (OR) = 2.51, confidence interval (CI): 1.65–
3.81). Patients ≤50 years had higher positivity prevalence com-
pared to patients ≤18 years (sig. = 0.021; adjusted OR = 3.45, CI: 
1.20–9.86). Patients who lived in cold regions had significantly 
more prevalence of positivity (no. of cases = 403; sig. = 0.043 and 
crude OR = 1.86, CI: 1.02–3.39) and higher rate of index ≥1.5 
(sig. = 0.017; crude OR = 3.99, CI: 1.79–8.88). Disease onset age 
between 28 and 37 years was more positive compared to 
18–27 years (N = 480; sig. = 0.02; adjusted OR = 1.85, CI: 1.09–
3.14) but correlated reversely with index (sig. = 0.01).
Conclusion: Age, male gender, onset age, and cold area residency 
significantly influenced anti-JCV antibody positivity prevalence. 
Only age of onset and cold area residency related to the index. No 
significant difference was observed between the previous type of 
disease-modifying drugs, dosage and duration of treating with 
them, and anti-JCV antibody positivity and its index.
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Background: The efficacy and safety of ocrelizumab in relapsing 
multiple sclerosis (RMS) have been demonstrated in the OPERA 
trials. Upon completion of the controlled treatment period, all 
patients were eligible to enter an ocrelizumab open-label exten-
sion (OLE) phase. The objective is to preliminarily assess annual-
ized relapse rate (ARR) at 144 weeks among patients with RMS 
who received ocrelizumab or interferon beta-1a (IFNβ-1a) in the 
Phase III 96-week OPERA I and II trials, followed by ocrelizumab 
in an OLE.
Methods: During the controlled treatment period, patients 
received intravenous ocrelizumab 600 mg every 24 weeks or sub-
cutaneous IFNβ-1a 44 µg three times weekly for 96 weeks. 
During the OLE, patients from the IFNβ-1a group were switched 
to ocrelizumab.
Results: Patients from OPERA I (ocrelizumab, 352/410; IFNβ-1a, 
326/411) and OPERA II (ocrelizumab, 350/417; IFNβ-1a, 297/418) 
enrolled in the OLE. At the time of analysis, 317 (90.1%) and 322 
(92.0%) continuous ocrelizumab patients and 307 (94.2%) and 268 
(90.2%) patients switching from IFNβ-1a in OPERA I and II, 
respectively, had ≥48 weeks of follow-up in the OLE (144 weeks 
total). Across groups, patients received a median of two doses of 
ocrelizumab in the OLE. Among patients switching from IFNβ-1a 
to ocrelizumab, the unadjusted ARR improved from 0.245 and 
0.254 over 96 weeks in OPERA I and II, respectively, to 0.092 and 
0.115 in the OLE. Among continuous ocrelizumab patients, the 
unadjusted ARR was 0.136 and 0.138 in OPERA I and II, respec-
tively; during the OLE, the ARR in this group was 0.118 and 0.100, 
respectively. Imaging metrics will be presented.
Conclusion: Patients who originally received ocrelizumab in the 
OPERA studies continued to have favorable ARR outcomes in 
the OLE. Patients who switched from IFNβ-1a to ocrelizumab in 
the OLE rapidly experienced ARR outcomes consistent with 
those of patients who received continuous ocrelizumab.
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autoimmune diseases in MS patients treated with interferon 
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Background: The incidence of thyroid dysfunction and autoim-
mune diseases in multiple sclerosis (MS) patients who received 
interferon has been reported in various studies . The mechanism 
by which interferon therapy leads to thyroid disease is unknown 
but the results of various studies suggest interactions of the 
immune system with the direct toxic effects of interferon on thy-
roid cells. However, there is not much information about these 
damages in MS patients who take interferon for a long time. Due 
to this limitation, this study was conducted with the aim of deter-
mining the prevalence of thyroid functional disorders and autoim-
mune diseases in patients with MS treated with interferon beta for 
less than 5 years.
Methods: One hundred MS patients who had been treated 
with interferon beta (the case group) and 30 MS patients who 
had not yet started treatment with interferon (the control 
group) were included in the study. All patients were examined 
for the presence of thyroid disorders (using the following 
tests: TSH, free-T3, and free-T4) and for the presence of auto-
immune thyroid disease (using the following tests: anti-TPO 
and anti-TG).
Results: The prevalence of functional disorders (18% vs. 3.3% 
and p = 0.04) and the prevalence of autoimmune thyroid dis-
eases (38% vs. 7.16% and p = 0.02) was significantly higher in 
patients with MS taking interferon beta than MS patients not 
taking interferon beta. Also, there was a significant relation-
ship between the duration of consumption of interferon beta 
with thyroid dysfunction (p =0.03) and with autoimmune thy-
roid disease (p =042).
Conclusion: The findings of our study showed that in MS 
patients there is a significant relationship between the preva-
lence of functional disorders and the prevalence of autoim-
mune thyroid diseases with consumption and duration of 
consumption of interferon beta. These findings indicate the 
need for careful and systematic investigation of MS patients 
after treatment with interferon in order to detect any thyroid 
damages early and ensure appropriate treatment measures are 
taken in the early stages.
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Demographic and clinical feature among patients with 
neuromyelitis optica in Iran
Sharareh Eskandarieh, Mohammad Ali Sahraian, Amir Reza 
Azimi, Abdalreza Naser Moghadasi, Sogol Koolaji and Narges 
Sistany Allahabadi
MS Research Center, Neuroscience Institute, Tehran University 
of Medical Sciences, Tehran, Iran
Background: Neuromyelitis optica (NMO) is a rare disease and 
epidemiological data on NMO are limited. The goal of this study 
was evaluation of demographic and clinical features of NMO in 
Caucasian population in Tehran, Iran.
Methods: A cross-sectional study among patients registered with 
NMO diagnosis was performed in Tehran during 2015–2016. We 
design a questionnaire to cover the epidemiological and clinical 
data of NMO in Tehran. Structured face-to-face interviews were 
conducted with 147 patients. The logistic regression was applied 
in analysis via software package SPSS.
Results: Among 147 patients, mean age was 36.09 years and 127 
(86.4%) were female. Mean of disease onset age was 31.53 years. 
Totally, 61 (46.6%) patients had a history of head trauma with 
59% NMO-Ig G positivity, but it was not significantly higher than 
patients with no history of head trauma (p = 0.38; odds ratio 
(OR) = 1.44 (0.72–2.87). NMO-IgG was positive in 71 (54.2%) 
patients and did not differ significantly between male and female 
(female positivity = 56.3%, male positivity = 42.1%; p = 0.32). A 
total of 42.2% of patients had primary presentation by transverse 
myelitis (TM) and optic neuritis (ON). In the next rank were 
patients presented only with TM (25.9%) or ON (18.4%).
Conclusion: NMO is higher among female and younger age. 
Most NMO patients present with TM and ON. Sex and history of 
head trauma did not significantly influence NMO-IgG positivity.
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Evaluation of no evidence of progression or active disease 
(NEPAD) in patients with primary progressive multiple 
sclerosis in the ORATORIO trial
Xavier Montalban1, Jerry Wolinsky2, Ludwig Kappos3, Stephen 
L Hauser4, Gavin Giovannoni5, Jerome de Seze6, Amit Bar-Or7, 
Donna Masterman8, Corrado Bernasconi9, Wei Wei9, Hideki 
Garren8, P Chin8, S Belachew9 and DL Arnold10,11
1Vall d’Hebron University Hospital, Barcelona, Spain; 
2McGovern Medical School, UTHealth, Houston, TX, USA; 
3University Hospital of Basel, Basel, Switzerland; 4University 
of California, San Francisco, San Francisco, CA, USA; 5Queen 
Mary University of London, London, UK; 6University Hospital 
of Strasbourg, Strasbourg, France; 7University of Pennsylvania, 
Philadelphia, PA, USA; 8Genentech, Inc., South San Francisco, 
CA, USA; 9F. Hoffmann-La Roche Ltd., Basel, Switzerland; 
10McGill University, Montreal, QC, Canada; 11NeuroRx 
Research, Montreal, QC, Canada
Background: Primary progressive multiple sclerosis (PPMS) is 
characterised by steadily increasing neurologic disability. No evi-
dence of progression or active disease (NEPAD), a novel endpoint 
that assesses the combined absence of composite disability pro-
gression and clinical and magnetic resonance imaging (MRI) dis-
ease activity, is investigated here in patients with PPMS.
Methods: In a post hoc exploratory analysis of the ORATORIO 
trial, 234 placebo- and 465 ocrelizumab-treated patients were 
evaluated to assess the proportion of patients with NEPAD from 
baseline to Week 120, defined as having no evidence of progres-
sion (NEP; no 12-week confirmed progression of ≥1/≥0.5 points 
on the Expanded Disability Status Scale if the baseline score was 
≤5.5/>5.5 points, respectively; no 12-week confirmed progression 
of ≥20% on the timed 25-foot walk test and nine-hole peg test), no 
brain MRI activity (no new/enlarging T2 lesions and no T1 Gd+ 
lesions) and no protocol-defined relapse. Brain MRI assessments 
were conducted at baseline and Weeks 24, 48 and 120.
Results: Compared with placebo, ocrelizumab increased the pro-
portion of patients with NEPAD at Week 120 (9.4% vs 29.9%; risk 
ratio ocrelizumab vs placebo (95% confidence interval (CI)): 3.15 
(2.07–4.79); p < 0.0001). A consistent effect of ocrelizumab was 
also observed on all three components of NEPAD. Sensitivity 
analyses will also be presented.
Conclusion: In ORATORIO, the proportion of patients with 
NEPAD increased approximately threefold with ocrelizumab 
compared with placebo. NEPAD may represent a useful compos-
ite outcome to assess the absence of clinical and MRI features of 
disease progression and activity in patients with PPMS.
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Comparing multiple sclerosis disability-adjusted life-years 
and years lived with disability among Iran and Middle East 
and North Africa in 2015
Narges Sistany Allahabadi, Sogol Koolaji, Sharareh Eskandarieh 
and Mohammad Ali Sahraian
MS Research Center, Neuroscience Institute, Tehran University 
of Medical Sciences, Tehran, Iran
Background: The years lived with disability (YLD) and disabil-
ity-adjusted life-years (DALYs) are critical health index for quan-
tifying burden of disease.
Methods: Based on epi-visualization interactive tool, we could 
explore data inputs and epidemiological estimates from the GBD 
2015 project to assess multiple sclerosis (MS) in Middle East and 
North Africa (MENA). MS prevalence and age-adjusted MS YLD 
and DALY’s rates in 2015 for both sexes in MENA were observed 
by organizing into hierarchy levels 3.
Results: Among 21 countries that were enrolled in this observa-
tional study, Iran had the highest age-adjusted DALY rate in both 
sexes (female: 30.98/100,000 (23.93–39.56) years, male: 
21.86/100,000 (17.01–28.42) years) and the lowest was for Kuwait 
(female: 7.76/100,000 (5.79–10.5) years, male: 6.07/100,000 
(14.82–7.52) years); also, the highest age-adjusted YLD rate in 
both sexes belonged to Iran (female: 18.62/100,000 (13.03–24.55) 
years, male: 8.78/100,000 (5.95–11.94) years) and the lowest was 
observed in Kuwait (female: 5.06/100,000 (3.42–6.96) years, 
male: 3.07/100,000 (2.12–4.15) years). These countries had high-
est and lowest prevalence of MS in both sexes among MENA 
countries (Iran female MS prevalence: 57.11/100,000, Kuwait 
female MS prevalence: 14.72/100,000), (Iran male MS prevalence: 
26.5/100,000, Kuwait male MS prevalence: 8.62/100,000). Mean 
of female DALY in the region was 13.97; standard deviation 
(SD) = 5.37 years. Mean of male DALY in the region was 10.37; 
SD = 4.36 years. Mean of female YLD in the region was 8.56; 
SD = 2.79 years, and for male YLD was 5.29; SD = 1.34 years.
Conclusion: In MENA, Iran had the highest age-adjusted DALY 
and YLD rate in both sexes which can be related to its highest MS 
prevalence in the region.
27
Years lived with disability changes in five income-level 
countries during 2000–2015
Narges Sistany Allahabadi, Sogol Koolaji, Sharareh 
Eskandarieh, Mohammad Ali Sahraian and Iman Izadpanah
MS Research Center, Neuroscience Institute, Tehran University 
of Medical Sciences, Tehran, Iran
Background: The years lived with disability (YLD) is a critical 
health index for quantifying burden of disease that can be effected 
by prevalence of multiple sclerosis (MS) and life expectancy (LE) 
index.
Methods: Based on epi-visualization interactive tool, we could 
explore data inputs and epidemiological estimates from the GBD 
2015 project to assess MS. We compared A-st YLD changes dur-
ing 2000–2015 according to MS prevalence and LE among five 
income-level countries by organizing into hierarchy levels 3.
Results: Among five income regions, highest A-st YLD rate in 
2000 and 2015 was for high-income countries (2000: 23.65 and 
2015: 25.86; 9.36% change rate (CR)); also, they had the highest 
MS prevalence (2000: 71.92/100,000 and 2015: 78.72/100,000). 
Low-income countries had the lowest MS prevalence (2000: 
6.59/100,000 and 2015: 7.14/100,000) and A-st YLD rate (2000: 
2.31 and 2015: 2.5; 8.1% CR), and the same trend was seen 
between MS prevalence and A-st YLD rate in high- to middle-
income region and the opposite in low–middle and middle-income 
countries. A-st YLD rate decreased in middle- to high-income 
countries (−6.06% CR; 2000: 5.87, 2015: 5.52) and increased in 
others with the highest change in low- to middle-income countries 
(9.57% CR; 2000: 4.08, 2015: 4.47). A-st YLD rate changes in 
middle-income countries was 6.76% (2000: 3.54, 2015: 3.78) and 
in Iran as a country with middle to high income was −8.72% 
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(2000: 14.95, 2015: 13.65). LE percent changes reversely related 
to income of the countries (low-income LE% change = 16.28% to 
4.61% in high-income countries). It decreased A-st YLD rate in 
all regions by nearly the same trend of A-st YLD percent changes, 
and again middle- to high-income countries had the most decrease 
in A-st YLD (11.91% CR).
Conclusion: Increase in LE CR had decreasing effect on A-st 
YLD changes in the nearly same order in all regions. YLD rate 
changes were related to MS prevalence changes’ trend in all 
regions except low–middle and middle income in which after 
adjusting YLD rate by prevalence, the differences of A-st YLD 
rate changes between middle-, high–middle and high-income 
countries decreased. The effect of MS prevalence on A-st YLD 
changes rate was more than life expectancy among different 
income regions.
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Durable improvements in clinical outcomes with 
alemtuzumab in patients with active relapsing–remitting 
multiple sclerosis in the absence of continuous treatment: 
7-year follow-up of CARE-MS I patients (TOPAZ study)
Jihad Said Inshasi1, Alexey N Boyko2, Jérôme De Seze3, Hans-
Peter Hartung4, Eva Havrdova5, Pamela McCombe6, Xavier 
Montalban7, Carlo Pozzilli8, Patrick Vermersch9 and David H 
Margolin10
1Rashid Hospital and Dubai Medical College, Dubai, United 
Arab Emirates; 2Pirogov Russian National Research Medical 
University & Demyelinating Diseases Center, Yusupov Hospital, 
Moscow, Russia; 3University of Strasbourg, Strasbourg, France; 
4Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 
5Charles University, Prague, Czech Republic; 6The University of 
Queensland, Brisbane, QLD, Australia; 7St. Michael’s Hospital, 
University of Toronto, Toronto, ON, Canada; 8Sapienza 
University of Rome, Rome, Italy; 9University of Lille, Lille, 
France; 10Sanofi, Cambridge, MA, USA
Background: Patients completing at least 48 months of the 
CARE-MS extension could enrol in the 5-year TOPAZ study 
(NCT02255656) for further long-term evaluation. Here, we report 
the 7-year efficacy and safety results from patients in the 
CARE-MS I study who received alemtuzumab.
Methods: In TOPAZ, patients can receive alemtuzumab retreat-
ment ≥12 months after the previous course or other disease-mod-
ifying therapy (DMT) at any time point (both per investigator 
discretion; no criteria); magnetic resonance imaging (MRI) scans 
are performed annually. Assessments: annualised relapse rate 
(ARR); 6-month confirmed disability worsening (CDW); 6-month 
confirmed disability improvement (CDI); no evidence of disease 
activity (NEDA); and adverse events (AEs).
Results: Of the 349 CARE-MS I patients who entered the exten-
sion, 321 (92%) remained on study until the end of Year 6 and 
then entered TOPAZ. Of those, 299 (93%) patients remained on 
study through Year 7. ARR remained low (0.13 at Year 7), and the 
proportion of patients with either stable or improved EDSS versus 
baseline remained high (78% at Year 7). Through 7 years, 74% of 
patients were free from 6-month CDW and 37% achieved 6-month 
CDI. The majority of patients achieved NEDA in each year (Year 
3: 62%; Year 4: 60%; Year 5: 62%; Year 6: 58%; and Year 7: 
61%). These effects were achieved with 59% of patients receiving 
no additional treatment (alemtuzumab or other DMT) after their 
initial two courses of alemtuzumab. Incidences of overall AEs, 
infusion-associated reactions, and infections decreased over time 
and were reduced versus the 2-year core study. Thyroid AE inci-
dence peaked at Year 3 and then declined.
Conclusion: Clinical efficacy of alemtuzumab was maintained 
for 7 years in treatment-naive patients, despite 59% receiving no 
additional treatment since the initial two courses of alemtu-
zumab. Additionally, improvement in disability was observed in 
37% of the patients. The safety profile of alemtuzumab remained 
consistent, and the overall incidence of AEs decreased over 
time. These findings suggest that alemtuzumab may provide a 
unique treatment approach for patients with relapsing–remitting 
multiple sclerosis (RRMS), offering durable efficacy in the 
absence of continuous treatment.
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Assessment of clinical disease activity and disability 
improvement by number-needed-to-treat analyses in patients 
with relapsing multiple sclerosis treated with alemtuzumab 
or ocrelizumab
Raed Alroughani1, Giancarlo Comi2, Regina Berkovich3, 
Guillermo Izquierdo4, Daniel Kantor5, Christopher LaGanke6, 
Volker Limmroth7, Richard AL Macdonell8, Basil Sharrack9 and 
Heinz Wiendl10
1Amiri Hospital, Sharq, Kuwait; 2Vita-Salute San Raffaele 
University, Milan, Italy; 3Keck School of Medicine of USC, 
University of Southern California, Los Angeles, CA, USA; 
4Virgen Macarena University Hospital, Seville, Spain; 5Florida 
Atlantic University, Boca Raton, FL, USA; 6North Central 
Neurology Associates, Cullman, AL, USA; 7Klinik für Neurologie 
und Palliativmedizin Köln-Merheim, Cologne, Germany; 8Brain 
Research Institute, The Florey Institute of Neuroscience & 
Mental Health, Melbourne, VIC, Australia; 9Sheffield Teaching 
Hospitals NHS Foundation Trust, Sheffield, UK; 10University of 
Münster, Münster, Germany
Background: We determined the number-needed-to-treat (NNT) 
to prevent clinical disease events and achieve disability improve-
ment versus subcutaneous (SC) interferon beta (IFNβ)-1a in 
relapsing multiple sclerosis (MS) studies of alemtuzumab and 
ocrelizumab.
Methods: NNT values were derived from post hoc analyses of the 
2-year data from the alemtuzumab 12 mg and ocrelizumab 600 mg 
studies. This analysis used alemtuzumab data from patients with 
active relapsing–remitting MS (RRMS; ≥2 relapses within the last 
2 years, with one or more relapse in the previous year) who were 
treatment-naive (CAMMS223 (NCT00050778) and CARE-MS I 
(NCT00530348), N = 786) and those who had an inadequate 
response (≥1 relapse) to prior therapy (CARE-MS II 
(NCT00548405), N = 628). Ocrelizumab data were analysed from 
the OPERA I (NCT01247324, N = 821) and II studies 
(NCT01412333, N = 835) in patients with two or more clinical 
relapses within the previous 2 years or one clinical relapse in the 
previous year.
Results: Baseline mean Expanded Disability Status Scale 
(EDSS) scores (CAMMS223/CARE-MS I: 2.0; CARE-MS II: 
2.7; OPERA I: 2.9; OPERA II: 2.8), mean MS duration 
(CAMMS223/CARE-MS I: 1.9 years; CARE-MS II: 4.5 years; 
OPERA I and II: 6.7 years in each study) and mean number of 
relapses in the previous 2 years (CAMMS223/CARE-MS I: 2.5; 
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CARE-MS II: 2.8; OPERA I/II: 1.8 in each study) varied across 
the trials. Both alemtuzumab and ocrelizumab significantly 
reduced annualized relapse rate (ARR) and confirmed disability 
worsening (CDW) versus SC IFNβ-1a. NNT values versus SC 
IFNβ-1a were lower with alemtuzumab than ocrelizumab to 
prevent one relapse (CAMMS223/CARE-MS I: 5; CARE-MS 
II: 4; OPERA I/II: eight each), CDW in one patient (CAMMS223/
CARE-MS I: 15; CARE-MS II: 13; OPERA I: 23; OPERA II: 
21) and clinical disease activity (CDA) in one patient 
(CAMMS223/CARE-MS I: 5; CARE-MS II: 6; OPERA I/II: 8 
each). NNT values versus SC IFNβ-1a to achieve CDI in one 
patient were also lower with alemtuzumab than ocrelizumab 
(pooled CAMMS223/CARE-MS I/CARE-MS II: 10; pooled 
OPERA I/II: 25).
Conclusion: Acknowledging population differences in the data-
sets, fewer patients required treatment with alemtuzumab than 
ocrelizumab to prevent clinical events and achieve CDI over 
2 years in SC IFNβ-1a comparator studies. Further real-world 
clinical experience will help confirm these findings.
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Assessment of availability and usefulness of multiple sclerosis 
health education resources in Arabic
Samah Ishak1, Osama Al-Wutayd2, Nicoletta M Alexander1 and 
Mohammad Al-Jumah3,4
1Walden University, Minneapolis, MN, USA; 2Unaizah College 
of Medicine, Qassim University, Qassim, Saudi Arabia; 3King 
Abdulla International Medical Research Centre, King Saud bin 
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Background: Multiple sclerosis (MS)-related health educa-
tion and reliable information is significant to patients with MS 
(especially the newly diagnosed). Mounting evidence suggests 
that credible and continuous health information for patients 
improves symptoms’ management and treatment compliance 
and thereby contributes to better health outcomes. Despite the 
existence of many credible and evidence-based information 
resources in many languages, such information sources are 
lacking for Arabic-speaking patients and families, and little is 
known about the perceived trust in such information sources.
Methods: The cross-sectional study incorporated two phases. 
Phase 1 was a pilot study that included developing and validating 
the questionnaires to be used in the main study. It was conducted 
in a sub-sample of patients with MS, family/friends (n = 15), and 
a group of healthcare professionals (n = 5) for content validity and 
clarity of the two developed questionnaires. Phase 2 was con-
ducted on main study population of selected MS-related popula-
tion (patients and family/friends; n = 217. The questionnaires 
covered items on demographics; disease-related questions; infor-
mation resources used by respondents; and knowledge about, 
level of trust, and satisfaction on the newly enhanced Arabic web-
site (evidence-based) developed by the Saudi MS Advisory 
Group.
Results: The distribution of the patients with MS sample is simi-
lar to that of the general MS population in Saudi where female-to-
male ratio is 2:1, 65% of respondents were university graduates or 
above, and 50% were employed. In addition, 65% of the patients 
suffered previous relapses in the past 5 years with 52% having 
partial recovery and 41% with complete recovery. A total of 68% 
of all respondents had little or no prior knowledge about the dis-
ease until diagnosis. They also showed that the Internet and social 
media outlets were the sources most used by respondents in seek-
ing MS-related health information regardless of their characteris-
tics (∼90%). Availability of information through Internet and 
social media outlets was found to be significantly higher than 
other traditional media and news outlets (p-value = 0.01, odds 
ratio (OR): 3.65).
Conclusion: Although physicians are still regarded as the most 
trusted source of health information for patients with MS, the 
Internet and social media are the widely used sources of informa-
tion for most of them. This has important implications for the 
delivery and dissemination of MS-related health information for 
Arabic-speaking patients and their communities.
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Relationship between neutrophil-to-lymphocyte ratio and 
stress in patients with multiple sclerosis
Meshal Mohammed Alfallaj1, Fawaz Al-Hussain2, Meshal 
Mohammed Alfallaj1, Abdulaziz Nasser Alahmari1, Abdullah 
Nasser Almazyad1, Talal Khalid Alsaeed1, Abdulmjeed 
Abdulaziz Abdurrahman1, Ghulam Murtaza2 and Shahid Bashir1
1Department of Physiology, College of Medicine, King Saud 
University, Riyadh, Saudi Arabia; 2Department of Neurology, 
King Saud University, Riyadh, Saudi Arabia
Background: Multiple sclerosis (MS), a disease of autoimmunity 
and inflammation, is characterized by deterioration of the myelin 
sheath that protects the nerve fibers. The high levels of neutrophils 
in serum may be related to the chronic inflammation and caused 
by other triggers such as infections that have been associated with 
relapses in MS.
Methods: It was a retrospective study on 60 patients with MS and 
60 age- and sex-matched healthy controls. Patients with MS were 
evaluated for their eligibility for inclusion as complete clinical 
data containing laboratory records, complete blood count (CBC), 
and disease activity score (DAS) score. Matched healthy subjects 
without any risk factors or chronic diseases were included as con-
trols. We measured DAS score, neutrophil-to-lymphocyte ratio 
(NLR), calcium, phosphate, magnesium, chloride, alkaline phos-
phatase, and albumin serum levels in patients with MS and in 
healthy controls.
Results: The mean age was not significantly different in both 
case and control groups. The case and control groups were simi-
lar in terms of sex; however, the majority of the MS group was 
female. The NLR values of patients with MS were significantly 
higher than those of the healthy controls (p < 0.001). The NLR 
values were also significantly (p < 0.001) correlated with stress 
score.
Conclusion: MS is a disease of axonal degeneration and demy-
elination leading to unalterable damage to the central nervous 
system (CNS). The transfer of autoreactive T cells from the blood 
to the CNS is the key moment in the pathogenesis of MS, which 
starts a whole flow of imbalances in various chronic inflamma-
tory diseases. NLR could be considered as a quick, cheap, easily 
measurable, and inflammatory marker for assessment of inflam-
mation in patients with MS. The role of NLR in MS must be 
explored further.
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An update on pregnancy outcomes following ocrelizumab 
treatment in patients with multiple sclerosis and other 
autoimmune diseases
Sandra Vukusic1, Ludwig Kappos2, Sibyl Wray3, Silvia Bader-
Weder4, Regine Buffels4, Donna Masterman5, Julie Napieralski4 
and Stephen L Hauser6
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South San Francisco, CA, USA; 6University of California, San 
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Background: Ocrelizumab, a humanised monoclonal antibody that 
selectively targets CD20+ B cells, is approved by the Food and Drug 
Administration for the treatment of relapsing and primary progressive 
forms of multiple sclerosis (MS) and has also been studied in clinical 
trials for rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE). The objective is to provide an update of pregnancy outcomes 
in women treated with ocrelizumab during clinical trials.
Methods: This analysis includes pregnancies in women with MS, 
RA and SLE in ocrelizumab clinical trials (dose range 20–2000 mg) 
up to 31 January 2017. Across trials, women of childbearing poten-
tial were required to use two methods of contraception and continue 
contraception for 48 weeks after the last ocrelizumab infusion or 
until B cells repleted, whichever was longer. Urine pregnancy tests 
were performed at all infusion visits; if positive, dosing was stopped 
and the result confirmed with a serum pregnancy test. An embryo/
foetus was considered exposed to ocrelizumab in utero if the last 
infusion occurred within 3 months of conception or during preg-
nancy or if the date was unknown. All pregnancies occurring during 
clinical trials were followed to determine outcome.
Results: As previously reported, between 2008 and 14 September 
2015, 46 women randomised to ocrelizumab in clinical trials (15 
MS, 10 SLE, 21 RA) reported 48 pregnancies (15 MS, 11 SLE, 22 
RA). This cumulative update provides approximately 16 months’ 
additional data on pregnancies in clinical trials up to 31 January 
2017 and will review 58 pregnancies reported in 56 women (25 
MS and 31 non-MS). Among the 25 pregnancies in patients with 
MS, 13 were considered to have foetal ocrelizumab exposure. A 
total of 11 pregnancies had no foetal ocrelizumab exposure and 
one pregnancy is not assessable for foetal ocrelizumab exposure.
Conclusion: As a large proportion of patients with MS are women 
of reproductive age, pregnancy outcomes in patients exposed to 
ocrelizumab are important to understand. B-cell levels in neonates 
following maternal exposure to ocrelizumab have not been studied 
in clinical trials and the effect of ocrelizumab on the immune system 
of the newborn is unknown. Transient peripheral B-cell depletion 
and lymphocytopenia have been reported in some infants born to 
mothers exposed to other anti-CD20+ antibodies during pregnancy.
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Safety of ocrelizumab in multiple sclerosis: Updated analysis 
in patients with relapsing and primary progressive multiple 
sclerosis
Stephen L Hauser1, Ludwig Kappos2, Xavier Montalban3, Carol-
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David Wormser5 and Jerry Wolinsky6
1University of California, San Francisco, San Francisco, CA, 
USA; 2University Hospital of Basel, Basel, Switzerland; 3Vall 
d’Hebron University Hospital, Barcelona, Spain; 4Genentech, 
Inc., South San Francisco, CA, USA; 5F. Hoffmann-La Roche 
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Background: Two identical Phase III trials in relapsing multiple 
sclerosis (RMS; OPERA I (NCT01247324) and OPERA II 
(NCT01412333)) and the Phase III trial in primary progressive 
MS (PPMS; ORATORIO (NCT01194570)) evaluated the safety 
and efficacy of ocrelizumab. Ongoing safety reporting on disease-
modifying therapies for MS is crucial to understanding the long-
term benefit–risk profile. The objective is to report safety data 
from the follow-up of the global clinical trials of ocrelizumab in 
RMS and PPMS.
Methods: In the OPERA studies, patients with RMS were ran-
domised in a 1:1 ratio to receive intravenous ocrelizumab 600 mg 
every 24 weeks or subcutaneous interferon beta-1a (IFNβ-1a) 44 µg 
three times weekly for 96 weeks. In the ORATORIO trial, patients 
with PPMS were randomised in a 2:1 ratio to receive intravenous 
ocrelizumab 600 mg or placebo every 24 weeks for at least 
120 weeks. Following completion of the controlled treatment peri-
ods, Phase III patients were eligible to enter the ocrelizumab open-
label extension (OLE) phase of the trial. In a Phase II study in 
relapsing–remitting MS, patients were randomised in a 1:1:1:1 ratio 
to receive ocrelizumab 600 mg, ocrelizumab 2000 mg, placebo or 
intramuscular IFNβ-1a through Week 24, followed by ocrelizumab 
every 24 weeks through Week 96. Following a treatment-free period, 
eligible patients from the Phase II trial entered a long-term OLE in 
which ocrelizumab 600 mg was administered every 24 weeks. 
Safety outcomes were reported for all patients administered with 
ocrelizumab in Phase II and III MS clinical trials, including patients 
who switched to ocrelizumab from comparators. Long-term safety 
data will continue to be reported, particularly for serious infections, 
malignancies and any new signals that could arise.
Results: As of 17 February 2017, 2301 patients with MS received 
ocrelizumab, resulting in 7748 patient-years (PY) of exposure. 
Reported rates per 100 PY (95% confidence interval) were as fol-
lows: adverse events (AEs), 226 (222–229); serious AEs, 7.18 
(6.59–7.80); infections, 71.3 (69.5–73.2) and serious infections, 
1.86 (1.57–2.19). The incidence rate of malignancy was 0.454 
(0.316–0.632).
Conclusion: The updated safety profile in the ocrelizumab MS 
all-exposure population is generally consistent with that seen dur-
ing the controlled treatment period in the RMS and PPMS popula-
tions. Additional data from the ongoing follow-up will be reported.
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Rapidity of onset of ocrelizumab clinical efficacy in relapsing 
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Background: In relapsing multiple sclerosis (RMS), rapid con-
trol of clinical disease activity is an important treatment goal to 
minimize subsequent disability worsening. Ocrelizumab, a 
humanized monoclonal antibody that selectively targets CD20+ B 
cells, was superior in reducing clinical and magnetic resonance 
imaging (MRI) measures of disease activity compared with inter-
feron beta-1a (IFNβ-1a) over 96 weeks in two identical phase III 
trials in RMS (OPERA I and OPERA II). The objective is to assess 
the dynamics of onset of ocrelizumab effect on the risk of relapse 
over time and relapse rate by epoch compared with IFNβ-1a in the 
pooled OPERA I and OPERA II studies in RMS.
Methods: In the OPERA studies, patients were randomized 1:1 to 
receive intravenous ocrelizumab 600 mg every 24 weeks or sub-
cutaneous IFNβ-1a 44 µg three times weekly for 96 weeks. The 
primary endpoint in the individual studies was annualized proto-
col-defined relapse rate (ARR) by Week 96. The risk of first onset 
of protocol-defined relapse at various time points and ARR 
through Week 96 and at 8-, 24-, and 48-week epochs in the pooled 
OPERA studies were evaluated in post hoc exploratory analyses.
Results: In the pooled analysis, ocrelizumab reduced ARR from base-
line to Week 96 by 46.5% versus IFNβ-1a (0.156 vs 0.291; p < 0.0001). 
Kaplan–Meier analysis showed that ocrelizumab reduced the cumula-
tive probability of relapse versus IFNβ-1a as early as Week 8 (hazard 
ratio: 0.02 vs 0.04, p = 0.0142). Reductions in ARR with ocrelizumab 
versus IFNβ-1a were also observed in the baseline–Week 8 (0.12 vs 
0.27; p = 0.0045), baseline–Week 24 (0.18 vs 0.30; p = 0.0009), and 
baseline–Week 48 (0.16 vs 0.30; p < 0.0001) epochs.
Conclusion: In a pooled analysis of the OPERA studies, ocreli-
zumab reduced relapse occurrence versus IFNβ-1a throughout 
96 weeks, with significant reductions observed by Week 8.
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patients with multiple sclerosis due to pregnancy planning
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Background: The effect of pregnancy on long-term disability in 
women with relapsing–remitting multiple sclerosis (MS) is poorly 
understood. Our aim is to determine the association between 
delaying disease-modifying therapy (DMT) for pregnancy plan-
ning and long-term disability, as measured by the Expanded 
Disability Status Scale (EDSS), in women with relapsing–remit-
ting MS.
Methods: Using data from the Calgary MS Clinic database, we 
identified 426 women with EDSS <5, who delayed starting DMT 
for more than 1 year after it was recommended during the period 
1999–2006. Thirty-seven consenting women declined DMT due to 
planned pregnancy. EDSS at diagnosis was compared with EDSS 
at 5, 7, 10, and 15 years. The association between the cumulative 
time on DMT during the first 5 years of MS and EDSS change at 
5, 7, 10, and 15 years was determined. EDSS change in these 
women was then compared with EDSS change in two control 
groups of women also with relapsing–remitting MS, diagnosed 
between age 18 and 40 years, and who had an EDSS <5 when first 
advised to start DMT between 1999 and 2006: 101 women who 
delayed DMT for reasons other than pregnancy planning and 173 
women who started DMT within 1 year of diagnosis.
Results: Mean follow-up of the 37 women who delayed DMT due 
to planned pregnancy was 14.05 years. Prior to the diagnosis of MS, 
86.5% were nulliparous compared with 18.9% at the end of follow-
up. Mean time to pregnancy was 2.38 years from MS diagnosis and 
0.84 years from declining DMT for pregnancy planning. Eventually, 
67.6% of the patients started DMT. Mean time to initiating DMT 
was 4.02 years after declining DMT for pregnancy planning. 
Confirmed relapses occurred in 70.3% of women between declin-
ing DMT for pregnancy planning and starting DMT; the mean time 
to a relapse was 1.92 years. There was an increase in the mean 
EDSS score 15 years after diagnosis of 1.13 points (paired t-test, 
p = 0.002) among women who declined DMT for pregnancy plan-
ning. There was a moderate to high moderate negative correlation 
between the cumulative time on DMT during the first 5 years after 
the diagnosis of MS and EDSS change at 7 years (R = −0.49, 
p = 0.008), 10 years (R = −0.44, p = 0.017), and 15 years (R = −0.67, 
p = 0.006). When compared to the two control groups, change in 
EDSS scores at 5, 7, 10, and 15 years was not significantly different 
even after adjustment for age and EDSS at diagnosis.
Conclusion: Delaying DMT initiation for a planned pregnancy 
did not have a major impact of disability over 15 years in our 
patients despite the frequent occurrence of relapses and statisti-
cally significant change in EDSS. Greater time on DMT during 
the first 5 years after their MS diagnosis was associated with a 
statistically significant reduction in EDSS change.
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Background: To assess the dynamic of onset of ocrelizumab 
treatment effect on brain magnetic resonance imaging (MRI) 
activity compared with placebo and interferon beta-1a (IFNβ-1a) 
in a Phase II study in relapsing–remitting multiple sclerosis 
(RRMS). Rapid control of subclinical disease activity is an impor-
tant goal to minimize disability progression in MS. In clinical tri-
als in relapsing MS, ocrelizumab demonstrated superiority in 
reducing MS disease activity versus placebo and IFNβ-1a.
Methods: In the first 24 weeks of this Phase II trial, patients 
received placebo (n = 54), ocrelizumab 600 mg (n = 55), ocreli-
zumab 2000 mg (n = 55), or intramuscular IFNβ-1a 30 µg 
(n = 54). The primary endpoint was the total number of T1 gado-
linium-enhancing (Gd+) lesions at Weeks 12, 16, 20, and 24. 
Further exploratory analyses evaluated the total number of new 
T1 Gd+ lesions, new T2 lesions, and newly enlarging T2 lesions 
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by 4-week epochs for ocrelizumab 600 mg versus placebo and 
IFNβ-1a.
Results: Ocrelizumab reduced the total number of new T1 Gd+ 
lesions at Week 4 by 62% versus placebo (p = 0.0423) and the 
number of new T1 Gd+ lesions appearing between Weeks 4 and 8 
by 97% versus IFNβ-1a (p < 0.0001). The mean total number 
(adjusted rate) of new T2 lesions appearing between Weeks 4 and 
8 was 0 for ocrelizumab versus 0.717 for placebo and 0.609 for 
IFNβ-1a. Ocrelizumab reduced the total number of newly enlarg-
ing T2 lesions appearing between Weeks 4 and 8 by 93% versus 
placebo (p = 0.0030) and 90% versus IFNβ-1a (p = 0.0162). For 
each of the above endpoints, between-group differences favoring 
ocrelizumab versus placebo and versus IFNβ-1a were maintained 
at subsequent 4-week epochs through Week 24.
Conclusion: In this Phase II trial in RRMS, ocrelizumab demon-
strated beneficial effects on brain MRI activity versus placebo and 
IFNβ-1a as early as Week 4, supporting a rapid onset of action in 
suppressing brain lesions.
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Association between fatigue and cognition of multiple 
sclerosis in Hong Kong
Suen Wai Po
The Chinese University of Hong Kong, Hong Kong, China
Background: Multiple sclerosis (MS) is one of the common neu-
rological diseases characterized by chronic inflammatory demy-
elination in central nervous system. Cognitive impairment and 
fatigue are frequently reported in patients with demyelinating dis-
eases. This cross-sectional study aims to examine the cognitive 
profile and the correlation of fatigue level and cognitive function 
and to explore the predictors on the global cognition of patients 
with MS in Hong Kong.
Methods: In all, 30 participants diagnosed with demyelinating 
diseases were recruited. A collection of comprehensive cognitive 
test indices, Modified Fatigue Impact Scale (MFIS), and Kurtzke 
Expanded Disability Status Scale (EDSS) were used to evaluate 
the pattern of cognitive impairment, level of fatigue, and physical 
disability respectively. The performance of each cognitive meas-
ure was compared with the normative data in Hong Kong.
Results: Results indicated that 20% of the participants impaired in 
Hong Kong (HK)-Montreal Cognitive Assessment (MoCA) and 
there were 26.7% of them identified as fatigue in MFIS (scores 
≥38). No statistical significant difference was found in cognitive 
tests between fatigue and non-fatigue MS. Only trail making test 
(TMT) part B was moderately correlated with MFIS (r = −0.406, 
p < 0.05). Linear regression analysis revealed that EDSS was a sig-
nificant predictor to HK-MoCA score (β = −1.192, p < 0.01).
Conclusion: The study outlined the cognitive profile of MS 
cohort in Hong Kong and drew the conclusion that fatigue is cor-
related with the mental processing speed but not the global cogni-
tion, and neurological disability is a moderate predictor to the 
cognitive performance in patients with MS.
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Background: In recent years, the prevalence of multiple sclerosis 
(MS) has increased significantly in Tehran. Positive familial his-
tory of MS is one of the known factors increasing the risk of MS 
presentation. In this study, we estimated the prevalence and inci-
dence of MS in Tehran in the year 2016 while assessing associa-
tions among most important baseline characteristics of the 
patients.
Methods: A cross-sectional study was conducted in Iranian MS 
Society data from 1999 to 2016 and it investigated the most 
important variables related to the individual level for familial MS 
(gender, age at disease onset, and familial history of MS). Multiple 
regression was used to indicate the predictors of onset age of MS 
via SPSS.
Results: In all 18,061 patients with MS were included. The crude 
prevalence was 136/100,000 (95% confidence interval (CI): 114–
160), with female-to-male ratio of 3.06:1. MS age-standardized 
incidence rate was 1.8/100,000 of population (95% CI: 1.3–7.2). 
About 6.89% of the population had early-onset MS (≤18 years 
old); 13.37% of the male patients and 12.24% of the female 
patients had a history of familial MS. A total of 14.86% of the 
individuals with early-onset MS had familial history of MS com-
paring to 12.35% of the individuals with onset age more than 
18 years old, p = 0.01. The mean onset age of MS was 28.50, in 
individuals without familial history of MS (95% CI: 28.42–28.70; 
p = 0.007), 29.15 in males (28.88–29.42) and 28.29 in females 
(28.14–28.43). Gender was a strong significant predictor for onset 
age (p < 0.001).
Conclusion: While having increased MS prevalence in Tehran, 
the female to male ratio and incidence rate (comparing to previous 
studies) have decreased. The mean onset age of MS was signifi-
cantly higher in individuals without familial history than individu-
als with history of familial MS. Therefore, further research on 
genetic epidemiology of MS is needed.
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The prevalence and characteristics of neuromyelitis optica 
spectrum disorder in Tehran, Iran
Sharareh Eskandarieh1, Saharnaz Nedjat2, Amir Reza Azimi3, 
Abdorreza Naser Moghadasi3 and Mohammad Ali Sahraian3
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of Medical Sciences, Tehran, Iran; 2Knowledge Utilization 
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Background: Neuromyelitis optica (NMO) is an infrequent demy-
elinating disease, and epidemiological information on NMO is rare. 
The aim of this study was to estimate the prevalence, clinical fea-
tures, and serology of NMO in Caucasian population in Tehran, Iran.
Methods: A cross-sectional study was performed during 2015–
2016 in Tehran among patients registered with NMO diagnosis. A 
structured questionnaire was designed in MS Research Center to 
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measure the baseline characteristic, severity of symptoms, and 
significant epidemiological variables which were associated with 
NMO. The study was described for 103 registered patients, and 
data were collected from hospital database registry system and 
patient’s information through face-to-face interview. The logistic 
regression was applied in analysis by software package SPSS.
Results: The prevalence of NMO in Tehran was 0.86/100,000 in 2016 
with point prevalence rate of 1.35 and 0.26/100,000, respectively, for 
females and males. Female-to-male ratio was 5:1. The mean age at the 
disease onset was 31.54 years old. NMO-IgG was positive in 44 
(46.8%), and first presenting symptoms among patients were trans-
verse myelitis (TM) in 29 (28.2%), optic neuritis (ON; 23.3%), unilat-
eral declined visual acuity (17.47%), TM + ON (46.6%), and NMO 
with other appearances in 2 (1.9%). Based on our study, ON had sig-
nificant association with female gender. The adjusted odds ratio for 
sex was estimated for depression (odds ratio (OR) = 6.83; 95% confi-
dence interval (CI): 1.47–31.71), migraine (OR = 1.27; 95% CI: 1.13–
1.42), and hypothyroidism (OR = 1.25; 95% CI: 1.12–1.39).
Conclusion: We indicated that the risk of NMO is significantly 
higher among females and younger age group. Based on the 
results obtained from our study, ON had significant association 
with female gender and patients who had background of depres-
sion, migraine, and hypothyroidism.
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Background: Neuromyelitis optica spectrum disorder (NMOSD) 
is an autoimmune inflammatory disorder of the central nervous 
system. The aim of this study was to discover the environmental 
risk factors associated with a large sample of people with NMO.
Methods: A case–control study was conducted in Tehran among 
100 patients with a definite diagnosis of NMO. A structured ques-
tionnaire was designed to measure important epidemiological 
variables. A total of 400 control population were selected ran-
domly from 15- to 50-year-old residents of Tehran through digit 
dialing (RDD). Logistic regression was used to estimate unad-
justed, adjusted odds ratios (ORs), and 95% confidence intervals 
(CIs) via software package SPSS, version 23.
Results: Compared with the control population, in NMO patients 
the adjusted OR for low dairy consumption per week was 
OR = 18.09 (95% CI: 6.91–47.37), followed by low sea food 
intake (OR = 13.91; 95% CI: 6.13–31.57), low number of egg 
consumption (OR = 9.39; 95% CI: 4.03–21.86), low red meat con-
sumption (OR = 3.07; 95% CI: 1.68–5.62), low chicken consump-
tion (OR = 4.05; 95% CI: 1.59–10.35), and low fruit and vegetable 
consumption (OR = 6.23; 95% CI: 3.07–12.62). The lower light 
physical activity (OR = 6.32, 95% CI: 3.08–12.95) and lower 
heavy physical activity (OR = 16.11, 95% CI: 7.03–36.91) among 
patients had increased risk of NMO. A history of head trauma was 
risk of NMO (OR = 8.39, 95% CI: 4.97–14.16). A family aggrega-
tion of type 1 diabetics in sibling and mother was observed 
(OR = 12.63) and (OR: 7.61), respectively.
Conclusion: The low consumption of dairy, sea food, red meat, 
egg, fruit/vegetables, low physical activity and sun exposure, and 
head trauma were the main environmental risk factors in NMO.
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Background: Multiple sclerosis (MS) is associated with deficient 
serum 25 hydroxyvitamin D (25 (OH)D) level and cognitive 
impairment. The aim of this study is to evaluate cognitive perfor-
mance in patients with MS with deficient 25 (OH)D (<25 ng/mL) 
compared to patients with sufficient levels (>35 ng/mL) and then 
to evaluate the change in cognitive performance after 3 months of 
vitamin D3 oral replacement.
Methods: In all, 88 patients with relapsing–remitting MS and 
clinically isolated type of MS, older than 18 years, treated with 
interferon beta were enrolled. Cognitive testing was performed at 
baseline and at 3 months using the Montreal Cognitive Assessment 
(MoCA), Stroop, Symbol Digit Modalities (SDMT), and Brief 
Visuospatial Memory Test (BVMT-R). Serum 25 (OH)D was 
measured at baseline and at the end of the study.
Results: Vitamin D3 replacement improved the cognitive perfor-
mance in patients with MS after 3 months on MoCA and BVMT-
Delayed Recall (DR). Sufficient serum 25 (OH)D level predicted 
better cognitive performance on the BVMT-DR at baseline 
(β = 1.74, p < 0.008) and 3 months (β = 1.93, p < 0.01) after 
adjusting for all measured confounding variables.
Conclusion: Vitamin D3 replacement could improve cognitive 
performance in patients with MS and make a significant differ-
ence in the patient’s quality of life.
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Evaluation of sleep quality and risk assessment of obstructive 
sleep apnea among patients with MS
Omid Mirmosayyeb, Navid Manouchehri and Vahid 
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Background: Multiple sclerosis (MS) is a demyelinating disease 
characterized by deficient neural conduction and axonal loss. 
Fatigue as a common complaint of patients with MS has several 
possible explanations. Sleep disorder contributes to chronic 
fatigue, and decreased sleep quality is reported among patients 
with MS. We aimed to evaluate the sleep quality and risk of 
obstructive sleep apnea (OSA) among patients with MS and 
assess the correlation between the severity of the disease and sleep 
quality.
Methods: In all, 514 patients with MS including 70 men and 435 
women were enrolled in the study. Age range was 13–67 years. 
Basic demographic and disease characteristic data were collected 
from all patients. Disease severity was assessed using Extended 
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Disability Score Scale (EDSS). Sleep quality and sleepiness were 
assessed by Pittsburgh Sleep Quality Index (PSQI) and Epworth 
Sleepiness Score (ESS). Likelihood of OSA was assessed using 
the Berlin and STOP-Bang questionnaire.
Results: Regarding the quality of sleep, the mean ± standard 
deviation (SD) of PSQI score was 6.6 ± 3.2 with 60.9% of the 
patients having poor sleep quality. ESS results, however, 
showed that 8.6% of the patients reported mild to severe sleep-
iness during the day. With regard to likelihood of OSA, evalu-
ation of patients with STOP-BANG questionnaire revealed that 
13% of the patients had high risk for OSA; Berlin question-
naire also indicated that 21.2% of the patients had high likeli-
hood of sleep disordered breathing. PSQI scores were weakly 
correlated to the patients’ EDSS score (p = 0.02, r = 0.4). 
Berlin questionnaire results were also correlated to the patients’ 
EDSS score (p = 0.04, r = 0.35).
Conclusion: Our results indicate that patients with MS have poor 
sleep quality and that OSA could be partially relevant. We also 
found that MS severity directly affects sleep quality.
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Background: Pediatric multiple sclerosis (MS) has been increas-
ingly recognized. In the absence of approved disease-modifying 
therapies (DMTs) for pediatric patients, clinicians resort to data 
extrapolated from clinical trials conducted in adults with MS. The 
objective of this article was to study the effectiveness and safety 
of natalizumab in patients with pediatric MS.
Methods: Patients with pediatric MS (age < 18 years) who had 
been treated with natalizumab were followed up prospectively 
as part of the national MS registry. Data of relapsing patients 
who had at least 1-year follow-up data were analyzed. The pri-
mary outcome measure was the annual relapse rate after natali-
zumab treatment. Secondary outcome measures included the 
mean change in disease progression measured by the Expanded 
Disability Status Scale and the proportion of patients with radio-
logic activity (gadolinium-enhancing or new T2 lesions) at the 
last follow-up visit.
Results: In all, 32 patients with pediatric MS had been treated 
with natalizumab for at least 12 months, of whom 72% were 
females. The mean age at onset and disease duration was 
14.9 ± 2.6 and 5.1 ± 3.1 years, respectively. Most patients (n = 21, 
66%) had breakthrough disease on first-line DMTs. The mean 
number of natalizumab infusions was 34.5 ± 18. The annual 
relapse rate was significantly reduced (1.66 ± 0.5 vs 0.06 ± 0.25; 
p < 0.001), whereas the mean Expanded Disability Status Scale 
improved (3.3 ± 1.3 vs 2.2 ± 1.0; p < 0.001) at the last follow-up 
visits. The proportion of patients with magnetic resonance imag-
ing activity was significantly reduced (93.8% vs 12.5%; 
p < 0.001). No major adverse events were observed.
Conclusion: In our pediatric MS who had cohort with aggressive 
or breakthrough disease, treatment with natalizumab was effective 
in reducing clinical and radiologic disease activity. Natalizumab 
has a similar clinical efficacy and safety profile as in adult MS.
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evidence
Raed Alroughani1, Samar Ahmed2, Raed Behbehani2 and Jasem 
Al-hashel3
1Amiri Hospital, Kuwait City, Kuwait; 2Ibn Sina Hospital, 
Kuwait City, Kuwait; 3Kuwait University, Kuwait City, Kuwait
Background: Dimethyl fumarate (DMF) has been recently 
approved as a disease-modifying therapy for the treatment of mul-
tiple sclerosis (MS). Post-marketing studies are important to con-
firm what was established in clinical trials.
Methods: Using the national MS registry, we prospectively 
assessed relapsing patients with MS who had been prescribed 
DMF for at least 6 months. Primary outcome measure was the 
proportion of relapse-free patients at last follow-up visit. 
Secondary outcome measures were the mean change in Expanded 
Disability Status Scale (EDSS) and the proportion of patients 
with radiological activity (gadolinium-enhancing or new T2 
lesions) at the last follow-up visit. Absolute lymphocyte count 
(ALC) was assessed at baseline (within 6 months prior to DMF 
initiation) and at one or more times during DMF treatment 
3 months post-initiation.
Results: Of 134 patients identified, 119 were eligible and included 
in the analysis. Women represented 59.7% of the studied cohort. 
Mean age and mean disease duration were 33.5 ± 11.1 and 
8.3 ± 7 years, respectively. A total of 75.6% of the patients 
received prior disease-modifying therapies. Mean duration of 
DMF exposure was 20.5 ± 9.5 months. The proportion of relapse-
free patients increased significantly from 51.2% to 89.9% 
(p < 0.0001), while the mean EDSS score decreased from 2.8 ± 1.8 
at baseline to 2.3 ± 1.7 (p = 0.058) at last follow-up visit. The 
proportion of patients with magnetic resonance imaging (MRI) 
activity decreased significantly from 61.1% to 15.1% (p < 0.0001). 
The mean ALCs decreased from 2170 to 1430 cells/µL (34% 
decrease). Lymphopenia was seen in 13 (10.9%) patients, of 
whom 3 (2.5%) patients had grade 3 lymphopenia necessitating 
discontinuation of DMF. Although no serious adverse events were 
reported, 19.3% of patients discontinued DMF.
Conclusion: In clinical practice, DMF appeared to be effective in 
reducing disease activity and progression of disability throughout 
the observational period. DMF was well tolerated with no serious 
adverse events. ALC profiles in DMF-treated patients were gener-
ally stable throughout the observational period. The proportion of 
patients who developed severe lymphopenia was similar to fig-
ures in clinical trials.
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Rate of multiple sclerosis relapse occurrence in pregnancy 
and post-partum period
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Background: Although multiple sclerosis (MS) relapse rates are 
often reduced during pregnancy, disease reactivation may be of 
concern after withdrawals of disease-modifying therapies (DMTs) 
prior or at the time of pregnancy confirmation.
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Methods: We conducted a retrospective cross-sectional study 
using the national Kuwait MS registry to identify pregnant women 
between 1 October 2011 and 30 September 2016. Data on demo-
graphics and clinical characteristics including relapses, prior use 
of DMTs, and pregnancy outcome were extracted. The primary 
outcome measure was the rate of relapse occurrence during preg-
nancy and the post-partum period. Furthermore, we investigated 
the relationship between the use of different DMTs and their 
washout periods and relapse occurrence.
Results: The medical records of 73 pregnancies (68 patients) were 
reviewed. Mean age and mean disease duration at the time of preg-
nancy confirmation were 28.2 ± 4.2 and 4.11 ± 3.9 years, respec-
tively. Most patients (88.2%; n = 60) were on DMTs in the year 
prior to pregnancy. Beta-interferons were the most prescribed 
medications (42.6%) followed by natalizumab (25%) and fingoli-
mod (19.1%). Thirteen relapses occurred in 16.2% of patients dur-
ing pregnancy, 7 and 5 of which occurred in first and third 
trimesters, respectively. Natalizumab and fingolimod were associ-
ated with relapses in the first trimester. Additional 10 relapses were 
recorded during post-partum period within 6.2 ± 5.6 weeks of 
delivery. Four miscarriages/spontaneous abortions were recorded.
Conclusion: The rate of relapse occurrence during pregnancy is 
higher than expected. Most relapses clustered in the first trimester 
suggesting that disease reactivation was associated with with-
drawal of high-efficacy DMTs and closely related to the washout 
period prior to pregnancy. Future studies are needed to address the 
adequate washout period prior to conception and best time to rein-
stitute DMTs in highly active patients.
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Background: Multiple sclerosis (MS) is a chronic neurological 
disease with heavy economic and social burdens resulting in sig-
nificant disability and social dependence. The prevalence of MS is 
in an upward trend in Kuwait reaching 85.05/100,000 in 2011.
Methods: A cross-sectional study using Kuwait National MS reg-
istry was conducted to estimate the costs of utilization of resources. 
Data of patient demographics, clinical features, and diagnostic/
therapeutic utilizations between 2011 and 2015 were extracted. 
This study aims to measure the cost of health resources’ utilization 
by patients with MS and to examine the difference in utilization 
and its attributed costs among patients with different types of MS 
and Expanded Disability Status Scale (EDSS) scores. Kruskal–
Wallis test was used to examine the difference between costs in 
different types of MS and EDSS scores.
Results: By end of 2015, 1344 patients with MS were included in 
the registry, of which 75.9% were of relapsing–remitting (RR) form 
and 83.3% had EDSS scores ≤3. The average annual cost per patient 
with MS has increased from 4532 KD in 2011 to 6753 KD in 2015. 
Utilization of disease-modifying therapies (DMTs) was the main 
driver of costs reaching 89.9% in 2015. The number of treated 
patients increased by 12.7% due to the availability of oral DMTs. 
Throughout the 5-year period, relapse severity decreased as the pro-
portion of relapses treated in ambulatory settings increased by 5.8% 
while hospitalizations decreased by 2.6%. There was a significant 
difference between the average cost per patient in different types of 
MS and different EDSS categories (p < 0.0001), with patients with 
RR course and moderate EDSS score (3.5–6) having the highest 
average of 7144 KD and 10,544 KD, respectively.
Conclusion: MS has a significant economic burden on the Kuwait 
healthcare system. DMTs seem to be the main driver of cost.
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Assessment of lymphopenia in patients with multiple sclerosis 
treated with dimethyl fumarate in a real clinical setting
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Background: Dimethyl fumarate (DMF), a disease-modifying 
therapy for multiple sclerosis (MS), causes lymphopenia in a frac-
tion of patients. Since lymphocytes contribute to MS pathology, 
lymphopenia may be a biomarker for response to the drug or for 
serious adverse events such as infections.
Methods: Using the national MS registry, a retrospective study 
was conducted to identify patients with MS who received DMF. 
Patients included in the analyses received at least 3 months’ pre-
scription and had absolute lymphocyte count (ALC) values avail-
able at baseline (within 3 months prior to DMF initiation) and at 
least twice 3 months post DMF initiation. Grades of lymphopenia 
were assigned according to the common terminology criteria for 
adverse events: grade 1 ALC <lower limit of normal to 800/mm3, 
grade 2 ALC <800–500/mm3, and grade 3 ALC <500–200/mm3. 
The primary outcome of the study is to evaluate ALCs in patients 
with MS treated with DMF in a real clinical setting.
Results: A total of 54 patients met the inclusion criteria, of whom 
66.7% were females. Mean age and mean disease duration were 
32.3 ± 11.4 and 6.9 ± 6.8 years respectively. Most patients (74.1%) 
received prior disease-modifying therapies. The mean ALCs 
decreased from 2190 to 1510/mm3 (∼30% decrease) over a mean 
duration of 11.7 ± 5.86 months. Among patients who had at least 
two follow-up ALCs, lymphopenia was seen in 22.2% of patients. 
Grade 1 and 2 ALCs were observed in 11.1% and 7.4% of patients, 
respectively, while 3.7% of the patients had grade 3 lymphopenia 
necessitating interruption or discontinuation of DMF.
Conclusion: ALC profiles in DMF-treated patients were gener-
ally stable throughout the observational period. The proportion of 
patients, who developed severe lymphopenia, was similar to fig-
ures reported in clinical trials. Further studies are needed to assess 
the time of ALC recovery in severely lymphopenic patients.
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The use of alemtuzumab in patients with multiple sclerosis in 
a clinical setting: Kuwait’s experience
Raed Alroughani1, Samar Ahmed2, Raed Behbehani2 and Jasem 
Al-hashel3
1Amiri Hospital, Kuwait City, Kuwait; 2Ibn Sina Hospital, 
Kuwait City, Kuwait; 3Kuwait University, Kuwait City, Kuwait
Background: Alemtuzumab is an anti-CD52 monoclonal anti-
body which has demonstrated efficacy in clinical trials and has 
recently been approved for treatment of patients with multiple 
sclerosis (MS) in Kuwait.
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Methods: Using the national Kuwait MS registry, patients with MS 
who received alemtuzumab and had at least 6-month follow-up were 
identified. Demographics, clinical and magnetic resonance imaging 
(MRI) characteristics, and adverse events were collected. The pri-
mary outcome is to examine the efficacy and safety of alemtuzumab 
treatment in a clinical setting. Patients’ status pre- and post-treatment 
was compared using chi-square and Student’s t-tests.
Results: A total of 20 patients were included of whom 60% (n = 12) 
were female. The mean age and disease duration of the cohort were 
31.8 ± 6.3 and 11.2 ± 5.2 years, respectively. The cohort included 14 
patients with relapsing and 6 with active progressive MS. Most 
patients (90%) received prior disease-modifying therapies, while 
two naive patients received alemtuzumab due to their aggressive and 
highly active disease. The mean follow-up duration after the first 
infusion of alemtuzumab was 17.7 ± 7.1 months with 55% of the 
patients receiving two courses of alemtuzumab. The annualized 
relapse rate was significantly reduced (0.1 vs 1.1; p < 0.001), and the 
mean Expanded Disability Status Scale (EDSS) score at last visit 
improved when compared to pre-treatment scores (3.6 ± 2.4 vs 
4.2 ± 1.9; p = 0.001). Only one patient continued to have persistent 
gadolinium-enhancing lesion on follow-up MRI. Majority of 
patients (n = 17) developed mild to moderate infusion-related reac-
tion and three patients developed autoimmune thyroiditis, two of 
whom were subclinical.
Conclusion: The effectiveness of alemtuzumab therapy in clini-
cal practice mirrors the results seen in pivotal clinical trials. 
Autoimmune thyroiditis is common necessitating prompt vigi-
lance and identification.
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Early changes in the normal appearing white matter 
in patients with acute optic neuritis using diffusion 
tractography
Ahmed Essmat Ali, Fath iMahmoud Afifi, Nabil Huusein 
Mohamed, Sabry Mohamed Fathi, Sayed Ahmed Fathi, 
Mohamed Foad Abdelmoety, Wael Osman and Hassan Gad 
Department of Neurology, Alazhar University, Cairo, Egypt
Background: Acute optic neuritis is the initial presentation in 
approximately 20% of cases of multiple sclerosis. Conventional 
magnetic resonance imaging (MRI) is sensitive for detecting brain 
lesions in most, but not all patients. Diffusion tractography provides 
information about the diffusion properties of water molecules and 
microstructural tissue changes not visible on conventional MRI.
Methods: This study included 26 patients with acute demyelinat-
ing optic neuritis and 10 age- and sex-matched healthy controls. 
All patients had normal conventional MRI brain. Diffusion MRI 
tractography was done to all patients within the first 3 days of 
onset. Diffusion parameters including apparent diffusion coeffi-
cient and fractional anisotropy were measured in different regions 
of white matter.
Results: Compared with controls, all patients showed significant 
decreased mean fractional anisotropy in the normal appearing 
white matter (p < 0.05). We found no significant difference in the 
apparent diffusion coefficient (ADC) values in patients when com-
pared with the control group (p > 0.05). The study showed that 
fraction anisotropy (FA) is more sensitive than ADC for detection 
of white-matter abnormalities in demyelinating optic neuritis 
patients. Corpus callosum is an early site for development of 
white-matter anisotropy changes in patients with optic neuritis.
Conclusion: Diffusion tractography seems to provide available 
means of indirectly detecting subtle changes in the normal 
appearing white matter not visible on the conventional brain 
MRI. FA is more sensitive than ADC to detect white-matter 
damage in demyelinating optic neuritis patients.
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Bilateral invasive breast carcinoma complicating treatment 
with natalizumab for multiple sclerosis
Mona M Alkhawajah1 and Alia MR Fallatah2
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Background: Natalizumab (NTZ) is a disease-modifying therapy 
(DMT), which was approved as a second-line treatment for 
patients with relapsing-remitting multiple sclerosis (RRMS) who 
are uncontrolled with first-line therapies, or as a first-line treat-
ment for highly active RRMS.
Case report: A 49-year-old lady was diagnosed with MS in 2004; 
she was treated initially with interferon-beta-1-a. Because of the 
continued disease activity, treatment was upgraded to NTZ. There 
was no evidence of disease activity following the upgrade. She 
received NTZ monthly infusions for 6 years. She has been regu-
larly assessed since 2011 for bilateral breast intra-ductal papil-
loma. In January 2017, mammogram and breast ultrasound were 
highly suspicious of malignancy. NTZ was discontinued. Biopsy 
showed invasive ductal carcinoma in both breasts.
Discussion: The risk of cancer in patients with MS is thought to be 
low. However, with the increasing use of immunomodulators, the 
risk becomes more concerning. We continue to learn more about the 
long-term effects of treatment with NTZ. Many papers in the litera-
ture describe the incidence of variable malignancies after treatment 
with NTZ for variable durations. Breast cancer has been seen in 
patients on NTZ, but thought to not exceed the rate in general popu-
lation. However, there is no further specification of the type of can-
cer or prognosis. The mechanism of action of NTZ might explain 
why breast cancer could be of a concern, knowing that integrin 
expression is reduced in breast cancer cells. It is reasonable to think 
that NTZ contributed to the malignant transformation of the benign 
breast lesions. In a risk evaluation study for malignant transforma-
tion of breast intraductal papilloma, only 1.1% were at risk.
Conclusion: We are raising the possibility of a higher risk of breast 
cancer in patients treated with NTZ. Although an association cannot 
yet be established, we propose that patients treated with NTZ need to 
be monitored carefully for the development of breast cancer, particu-
larly those with existing benign intraductal papilloma. The latter 
group might be better off treated with a different DMT. Alternatively, 
they could undergo a prophylactic surgical resection.
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Background: Cognitive performance is an indicator of disease 
progression in multiple sclerosis (MS). The Brief International 
Cognitive Assessment for Multiple Sclerosis (BICAMS) psycho-
metric characteristics were not established in Arabic-speaking 
populations. The objective of this study was to validate and pro-
vide normative data for the BICAMS in Arabic.
Methods: In this cross-sectional study, we will administer the 
modified BICAMS (mBICAMS) to 184 healthy subjects with no 
history of neurological disorders, traumatic brain injury, psychiat-
ric disorders, and cognitive impairment, age 16–90 years, and 50 
patients with MS in addition to screening to exclude participants 
with depression and/or cognitive impairment. mBICAMS consists 
of three tests: Symbol Digit Modalities Test (SDMT), Brief 
Visuospatial Memory Test — Revised (BVMTR), and a newly 
developed Verbal Memory Arabic Test (VMAT).
Results: To date, 93 participants were screened (10 excluded 
and 5 participants dropped out). In all, 77 healthy subjects (43 
females and 34 males) and 1 patient with MS completed the 
study, and retest was performed on 45 of these subjects after 
21 days (mean age 29.5 ± 10.8 years). SDMT yielded 
61.38 ± 8.96 correct answers (test–retest r = 0.64). On the 
VMAT, mean number of words recalled on the first five learn-
ing trials was 10.99 ± 1.49, short delay recall 11.23 ± 2.29, 
cued recall 11.53 ± 2.15, long delay recall 11.88 ± 2.29, cued 
recall 11.99 ± 2.24, and recognition trial 43.45 ± 1.98 out of 
45 words. VMAT showed acceptable test–retest reliability; 
r = 0.43. On the BVMT-R, participants scored 5.42 ± 2.42 on 
trial 1, 8.75 ± 2.42 on trial 2, and 10.42 ± 1.88 on trial 3 (test–
retest Cohen’s d = 1.15).
Conclusion: Recruitment and data collection are ongoing. 
Validating the mBICAMS allows accurate clinical use and 
research utilizations of these measures in the Arab world.
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Development of the Verbal Memory Arabic Test (VMAT)
Pia Zeinoun1, Natali Farran1, Samia Khoury2 and Hala Darwish1
1American University of Beirut, Beirut, Lebanon; 2American 
University of Beirut Medical Center, Beirut, Lebanon
Background: Verbal memory assessment requires the memoriza-
tion of words across several trials and recalling these words with 
and without aid across time. This testing type is integral to neu-
ropsychological assessment and is widely used in clinical and 
research settings. However, verbal memory tests are often trans-
lated from existing Western tools
a process that poses serious cultural and psychometric problems 
when interpreting the finding. Our study aimed to develop a test 
that is culturally and psychometrically robust to memory impair-
ment among Arabic-speaking people.
Methods: In order to identify 15 Arabic words that are culturally 
and linguistically appropriate, we recruited 77 normal adults from 
across Lebanon and asked them to generate words for seven 
semantic categories.
Results: We collected approximately 133 Arabic words per cate-
gory, selected those with low to medium frequency, and further 
selected words based on 11 conceptual criteria. The most appropri-
ate words constructed the primary memory list of 15 words (List 
A), and two lists served as interference (List B) and recognition 
items. The final version of the Verbal Memory Arabic Test (VMAT) 
comprised five trials of List A, followed by interference list, then 
immediate recall of List A with and without semantic cues, then 
delayed recall after 15 minutes, and finally a recognition trial.
Conclusion: The VMAT is the first neuropsychological tool 
developed intentionally as a culturally and linguistically valid ver-
bal memory test in Arabic. The next step is to provide normative 
data and evidence of its validity and reliability on 184 normal 
adults (older than 16 years), 50 patients with multiple sclerosis, 
and other special populations.
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Validation of MusiQoL among Arabic-speaking patients 
with MS treated with high-dose INF-β 1a SC injection new 
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Background: Validated quality-of-life (QOL) tools are not 
available for Arabic-speaking patients with multiple sclerosis 
(MS). 36-Item Short-Form (SF-36) and MusiQoL have been 
validated for other languages. The objective of this study was to 
prospectively assess and correlate MusiQoL with disease activ-
ity and progression among Arabic-speaking patients with MS 
treated with interferon beta-1 a subcutaneous (INF-β 1a SC) 
injection new formulation over 12 months.
Methods: The subjects comprised a prospective multinational, 
multicenter cohort study of Arabic-speaking patients with MS 
treated with rebif new formulation (RNF) for at least 6 months 
prior to entering the study. Their clinical parameters and QOL 
were assessed at baseline and by follow-up after 6and 12 months. 
Changes in MusiQoL total and subdomain scores were compared 
using the paired T-test. QOL changes from baseline and important 
parameters in QOL were correlated using Pearson and point bise-
rial methods.
Results: In all, 439 subjects from four Arabic-speaking countries 
were included. Their average age was 32.44 (±0.34) years, 71.5% 
were female, and 63.1% were educated to university level or above. 
The subjects had an average MS duration of 4.13 (±0.12) years, an 
average age at first attack of 27.35 (±0.26) years, and baseline 
Expanded Disability Status Scale (EDSS) of 2.05 ± 0.04. Overall 
QOL measured using SF-36 remained generally unchanged over 
time (p = 0.215). However, QOL change overtime measured using 
MusiQoL was statistically significant (p = 0.00015). Several aspects 
of subjects’ QOL including daily living activities, physical well-
being, symptoms, and coping improved. Sentimental and sexual life 
decreased overtime (p = 0.0072).
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Conclusion: The study suggests that the use of MusiQoL among 
Arabic-speaking patients with MS is a valid tool and may capture 
changes in several aspects of their clinical status over 12 months. 
Periodic assessment of QOL is recommended for management of 
patients with MS.
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Biotinidase deficiency mimicking seronegative neuromyelitis 
optica: Initially manifesting symptoms in adulthood
Mohammed Ahmed Saadah, Mohammed Ahmed Saadah, Loai 
Mohammed Saadah, Mahfoud Younis Albeshari, Abdulla 
Alromaithi, Tareq Afifi, Abdulmotaleb Mousa and Amani Ali 
Alzaabi
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Background: Young children with untreated biotinidase defi-
ciency (BD) may manifest variable symptoms based on their age 
of presentation. Older children, adolescents, and young adults 
may disclose predominant neurological deficits including para- or 
quadriparesis and visual loss.
Methods: We report a late-onset BD in a young adult who mim-
icked seronegative neuromyelitis optica.
Results: A 26-year-old man manifested as a disabling extensive 
cervical myelopathy and bilateral optic neuropathy, mimicking 
the findings of seronegative neuromyelitis optica. Neuroimaging 
was characterized by a magnetic resonance imaging (MRI) with 
T2/ fluid attenuated inversion recovery (FLAIR) hyper-intensity 
involving a long segment of the cervical spinal cord (bulbospinal 
junction-D2 segment) and bilateral optic nerves with moderately 
severe prolongation of P100 latency and moderate generalized 
brain atrophy. He was finally shown to have profound late-onset 
autosomal recessive BD with one copy inherited from either 
parent. He improved partially by oral biotin therapy.
Conclusion: This case record stresses the necessity to include BD 
as one of the mimickers in the differential diagnosis of patients 
with extensive myelopathy and/or bilateral optic neuropathy thus 
simulating seronegative neuromyelitis optica. This report sup-
ports the global newborn screening for this disorder.
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The application of stem cells in multiple sclerosis: An 
overview of open labels and ongoing studies
Saeid Bayat1, Saeid Shahbeigi1, Mandana Moheddin Bonab1, 
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Background: Mesenchymal stem cells’ (MSCs) therapy emerges 
as a potential new hope for patients with multiple sclerosis (MS).
Methods: We have reviewed the published and on-going clinical 
trials that have tried MSC for treating MS that have been regis-
tered in the clinical trial section of the PubMed or EMBASE.
Results: A total of 114 patients were enrolled in 11 cell-base stud-
ies with encouraging results. About 62% had clinical improve-
ment, 22% had a stable course, and 16% had a worsening course. 
Nine on-going trials will be done as double-blind studies; how-
ever, the remaining 10 studies are open label. Totally, from early 
registration of these studies in 2007 since completion of all studies 
in 2018, after about 11 years, 446 patients will be evaluated. 
Unfortunately, the enrollment criteria were clearly defined in only 
11 studies and sadly 6 of them have a similar initial Expanded 
Disability Status Scale (EDSS) and final outcome evaluation tolls. 
In other words, at the end of these studies we will have only 124 
patients enrolled in a similar referable study which would be 
unreasonable data for a good conclusion worldwide.
Conclusion: The cell-based therapies are safe and a reasonable 
therapeutic approach for progressive MS. Despite the good early 
results of MSC therapy in MS, it seems that the worldwide fashion 
about cell therapy in all parts of the world is so slow.
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Background: The aim of this study is to explore the frequency, 
type, and predictors of multiple sclerosis (MS) mimickers among 
patients referred with a recent diagnosis of MS to two specialized 
MS centers in the Middle East.
Methods: This is a retrospective review of a prospectively fol-
lowed cohort of patients with MS at two university specialized 
MS centers. All patients referred for MS were included. The final 
diagnosis was recorded, and demographic, clinical, laboratory, 
electrophysiological, and radiological variables were collected.
Results: A total of 554 patients were included in this study, of which 
431 were referred for diagnostic confirmation. The final diagnosis of 
MS was confirmed in 300 (70%), while 114 (26%) turned out to have 
an alternative diagnosis and 15 (3.5%) fulfilled criteria for radiologi-
cally isolated syndrome (RIS). The most common alternative diagno-
ses were psychogenic (16.3%), non-specific magnetic resonance 
imaging (MRI) white-matter lesions (14.7%), neuromyelitis optica 
(NMO) (9.5%), migraine (8.6%), and systemic autoimmune disor-
ders (8.6%). The strongest predictors of a final diagnosis of MS were 
as follows: younger age, presence of oligoclonal bands in the 
cerebrospinal fluid (CSF), periventricular, corpus callosum, spinal 
(p < 0.0001), or enhancing lesions (p < 0.005) on MRI.
Conclusion: Our study shows that 30% of patients referred for a 
suspicion of MS end up with a different diagnosis. The most com-
mon mimickers of MS in the Middle East are not different from 
what has been described in the Western countries. Age, MRI, and 
CSF findings can help with the differential diagnosis.
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Background: To evaluate the efficacy and safety of rituximab in 
multiple sclerosis (MS) in a clinical practice setting.
Methods: Clinical data of adult patients with MS treated with 
off-label rituximab at Nehme and Therese Tohme MS center in 
Lebanon between March 2008 and April 2017 were retrospec-
tively collected from medical charts. The main efficacy out-
comes were proportion of patients free from relapses, annualized 
relapse rate (ARR), disability progression as measured by 
Expanded Disability Status Scale (EDSS), and magnetic reso-
nance imaging (MRI) activity. Adverse events (AEs) were also 
recorded.
Results: A total of 64 rituximab-treated patients were included: 45 
relapsing–remitting MS (RRMS) and 19 progressive MS (n = 12 
secondary progressive MS (SPMS), n = 1 primary progressive MS 
(PPMS), and n = 2 relapsing-progressive MS (RPMS)). Patients 
were treated with 1000 or 2000 mg rituximab intravenous (IV) 
every 6–12 months for a mean duration of 31 ± 29 months. The 
subjects were 70.3% females with a mean age of 41.2 ± 12.8 years 
and mean disease duration of 7.7 ± 6.5 years. During treatment, the 
ARR decreased from 1.2 at baseline to 0.09 in patients with RRMS 
and from 0.3 to 0 in patients with progressive MS. The mean EDSS 
remained unchanged in RRMS and increased by 1.8 in patients 
with progressive disease. Between baseline and last follow-up, the 
percent of patients free from any new MRI lesions increased from 
16% to 89% in the RRMS group and from 47% to 100% in the 
progressive group. Infusion-related AEs occurred during 6.5% of 
infusions and were all mild. A total of 24 AEs (37.5%) were 
recorded. Two of our rituximab-treated patients experienced seri-
ous AEs requiring surgical interventions: pyoderma gangrenosum 
vaginalis with perianal abscess and fistula, and increase in the size 
of a benign Grade I meningioma. No case of progressive multifo-
cal leukoencephalopathy was detected.
Conclusion: Rituximab was well-tolerated and effective in 
reducing relapse rate and stabilizing disease in relapsing–
remitting and patients with progressive MS in our real-world 
clinical practice setting. Its efficacy persists with continued 
treatment and is similar to that reported in a recent cohort in 
Sweden.
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Background: We report a case of relapsing–remitting multiple 
sclerosis (RRMS) with severe rebound syndrome (RS) 12 weeks 
following discontinuation of teriflunomide therapy.
Case report: This is a case of a 38-year-old woman with RRMS 
of 9-year duration. She was diagnosed with RRMS in May 2008 
and was started on interferon-beta-1a 44 µg subcutaneously 
three times a week. She developed a second relapse in 2009 with 
bilateral lower extremities’ numbness and an increase in her 
Expanded Disability Status Scale (EDSS) to 3.0. A new brain 
magnetic resonance imaging (MRI) revealed one new lesion in 
the right temporal lobe but no evidence of enhancement. 
Her EDSS score improved to 1.5 after receiving a course of 
high-dose intravenous (IV) steroids, and she had no further 
relapses or new lesions on her annual brain MRIs until November 
2015 when she was switched to teriflunomide due to persistent 
flu-like symptoms and injection site reactions. Few months later, 
she developed significant side effects on teriflunomide including 
menorrhagia, severe and persistent hair loss, and gingival bleed-
ing leading to discontinuation of teriflunomide in October 2016. 
She decided to stay off treatment and in January 2017 developed 
right lower facial numbness, bilateral below-knee numbness, 
and gait imbalance with worsening of her EDSS to 3.5. She 
received a 5-day course of IV methylprednisolone but showed 
minimal improvement unlike her previous relapses. A month 
later, her condition worsened with increased lower extremities’ 
numbness and weakness. Her EDSS increased to 6 and she was 
unable to walk without support. An urgent brain and spine MRIs 
were obtained which showed multiple new lesions with more 
than 11 ring enhancing lesions as compared to the last MRI per-
formed in October 2016. Additional serological and cerebrospi-
nal fluid (CSF) studies were obtained to rule out any other 
infectious or inflammatory disorders but were all negative. Her 
symptoms improved significantly after a second course of IV 
steroids and her EDSS decreased to 1.5 by March 2017. She was 
kept on oral prednisone 60 mg daily for 2 weeks and then started 
on rituximab at a dose of 2000 mg given in two doses separated 
by 2 weeks.
Conclusion: We report a patient with severe disease reactivation 
12 weeks after stopping teriflunomide, consistent with the defini-
tion of RS. To the best of our knowledge, this is the first report of 
RS following discontinuation of teriflunomide.
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Background: Natalizumab is highly effective in multiple sclero-
sis (MS) but carries the risk of progressive multifocal leukoen-
cephalopathy (PML). It is postulated that extending the dosing 
interval from 4 to 5–8 weeks might decrease this risk by decreas-
ing the α4 integrin saturation on the surface of mononuclear cells. 
The aim of this study was to assess the effect of extended interval 
dosing (EID) on the therapeutic efficacy of natalizumab.
Methods: We reviewed all patients treated in our MS center with 
natalizumab for at least 6 months using EID. A total of 55 patients 
were shifted after an initial treatment period at standard interval 
dosing (SID) to an EID ranging from 5 to 8 weeks. All patients 
had a baseline magnetic resonance imaging (MRI) before initiat-
ing therapy and a follow-up MRI every 6 months thereafter.
Results: The mean treatment duration on SID and EID was 
16.7 ± 13.0 and 9.1 ± 6.4 months, respectively. The mean age of 
our patients was 35.9 ± 11.7 years, mean disease duration 
5.4 ± 6.4 years, 79.5% were females, and 94.5% had relapsing–
remitting MS as opposed to 5.5% with secondary progressive MS. 
Before initiating therapy, annualized relapse rate (ARR) was 0.83, 
mean EDSS 2.52 ± 1.5, and 63.6% of patients were JCV antibody 
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positive (antibody index ≤ 0.9 in 72.5% and ≥1.5 in 25.5% of 
cases). By the end of SID and EID treatment, 92.7% and 93.3% of 
patients were free of relapses (p = not significant (NS)) and the 
ARR decreased to 0.05 and 0.06, respectively (p = NS). The mean 
Expanded Disability Status Scale (EDSS) at the end of SID and 
EID periods was 1.7 ± 1.4 and 1.8 ± 1.3, respectively (p = NS). A 
total of 72.7% and 92.7% of patients were free of any new T2 or 
enhancing lesions on MRI during the SID and EID periods, 
respectively (p = 0.011). It is of note that in the SID group the 
baseline MRI was performed before starting natalizumab. The 
overall incidence of adverse events was 51% versus 31% during 
SID and EID periods, respectively. Specifically, the rate of infec-
tions was higher during SID compared to EID (42% vs 20%). 
There were no cases of PML.
Conclusion: In patients treated with natalizumab, shifting from 
SID to EID has no negative effect on efficacy as evidenced by 
relapse rate, disability progression, and MRI activity. The EID 
regimen is associated with a lower rate of infections and might 
potentially decrease the risk of PML.
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The Bayesian Risk Estimate for MS at Onset (BREMSO) 
correlates with cognitive and physical disability in patients 
with early multiple sclerosis
Marianne Said, Nabil El Ayoubi, Salem Hannoun, Bassem I 
Yamout, Ribal N Haddad and Samia J Khoury
Nehme and Therese Tohme Multiple Sclerosis Center, American 
University of Beirut, Beirut, Lebanon
Background: Prevention of long-term disability is the goal of 
therapeutic intervention in relapsing–remitting multiple sclerosis 
(RRMS). The Bayesian Risk Estimate for MS at Onset (BREMSO) 
was designed to give an individual risk score predicting disease 
evolution into secondary progressive MS (SPMS). The aim of this 
study is to investigate whether BREMSO correlates with physical 
disability, cognitive dysfunction, and regional brain atrophy dur-
ing the early disease course.
Methods: We investigated 100 patients with RRMS or clini-
cally isolated syndrome (CIS) enrolled in the AUBMC Multiple 
Sclerosis Interdisciplinary Research (AMIR) study, with at least 
2 years of follow-up and disease duration of less than 6 years. 
BREMSO score was calculated for all participants at disease 
onset. At each visit, cognitive function was assessed using the 
Symbol Digit Modalities Test (SDMT) and physical disability 
using the Multiple Sclerosis Severity Score (MSSS), Timed 
25-Foot Walk Test (T25-FW), and nine-Hole Peg Test (9-HPT). 
Of the 100 patients, 30 had a baseline magnetic resonance 
imaging (MRI) performed at the radiology department of the 
AUBMC. 3DT1 with gadolinium injection and three-dimen-
sional fluid attenuated inversion recovery (3DFLAIR) images 
were acquired. The intracranial volume (ICV) as well as the 
subcortical gray-matter structures and the corpus callosum 
(CC) were automatically segmented and their volumes 
measured.
Results: The mean (standard deviation (SD)) age was 28.1 
(11.19) years, MSSS 3.17 (2.36), and disease duration was 2.4 
(1.78) years. In multivariate linear regression analyses, control-
ling for age and education, the BREMSO score correlated nega-
tively with SDMT at visit 1 (β = −0.33 p = 0.019), visit 2 
(β = −0.34 p = 0.017), and visit 3 (β = −0.34 p = 0.014). BREMSO 
correlated positively with MSSS at visit 1 (r = 0.38, p = 0.006), 
visit 2 (r = 0.47, p < 0.0001), and visit 3 (r = 0.42, p = 0.002), but 
did not correlate with T25-FW and 9-HPT. MRI results showed a 
negative correlation between the BREMSO score and the CC vol-
ume at baseline (p < 0.03). No correlation was found between the 
BREMSO score and the intracranial volume and the subcortical 
gray-matter structures’ volume. This can be due to the small sam-
ple size or short interval follow-up.
Conclusion: The BREMSO score is directly correlated not just 
with the physical progression of the disease (MSSS) but also with 
the cognitive disability (SDMT and CC volume measurements) in 
early MS. Future studies might incorporate MRI measures into the 
BREMSO score increasing the sensitivity and specificity of this 
score.
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Correlation of fatigue with cognitive and physical disability 
using clinical outcomes and MRI measurements
Marianne Said, Salem Hannoun, Nabil El Ayoubi, Dania Bacha, 
Bassem I Yamout and Samia J Khoury
Nehme and Therese Tohme Multiple Sclerosis Center, American 
University of Beirut, Beirut, Lebanon
Background: Fatigue is an underestimated symptom affecting up 
to 95% of patients with multiple sclerosis (MS). It does not only 
exacerbate impairment but also affects a patient’s sense of control 
over the illness. In order to help patients cope with this disabling 
but treatable aspect of MS, it is necessary to understand the cor-
relation between fatigue domains, cognitive functioning, and 
physical ability.
Methods: Adult patients with MS diagnosed as relapsing–remit-
ting (RRMS) or progressive were clinically evaluated. The 
Modified Fatigue Impact Scale (MFIS) was administered to both 
MS and healthy age- and sex-matched control subjects. Processing 
speed was assessed using the Symbol Digit Modality Test 
(SDMT), and global brain atrophy was evaluated using magnetic 
resonance imaging (MRI) examinations. 3DT1 and three-dimen-
sional fluid attenuated inversion recovery (3D-FLAIR) images 
were acquired and processed. Intracranial volume (ICV) and sub-
cortical gray matter structures, lateral ventricles, and corpus cal-
losum were segmented and their volumes measured using the 
volBrain pipeline (http://volbrain.upv.es) and the SIENAX tool in 
FSL. Univariate analysis was performed to explore differences 
between subjects with and without fatigue. Multivariate analysis 
controlling for age, gender, education level, Expanded Disability 
Status Scale (EDSS), disease duration, clinical depression, and 
MS type and treatment was performed to see the correlations 
between fatigue and the different variables.
Results: One-hundred-and-thirteen patients with MS with mean 
disease duration of 8.6 years and 57 healthy subjects were 
recruited. Significant fatigue was seen in 32.3% of patients with 
MS and 6.2% of controls. Among fatigued MS participants, 66% 
and 75% had physical and cognitive fatigue, respectively. 
Multivariate analysis showed that SDMT correlated negatively 
with fatigue (p = 0.001, odds ratio (OR) = 0.88), more specifically 
with its cognitive domain (p = 0.003, OR = 0.9). In addition, phys-
ical fatigue positively correlated with EDSS (p = 0.04, OR = 1.4), 
particularly with the pyramidal Functional Systems (FS) score 
(p = 0.031, OR = 2.5). In multivariable linear regression and 
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adjusting for age, disease duration, EDSS, and depression, there 
was a negative correlation between MFIS scores and ICV 
(β = −0.54, p < 0.0001) and a positive correlation with the volume 
of lateral ventricles (β = 0.37, p = 0.006) and all-ventricular vol-
ume (β = 0.35, p = 0.007).
Conclusion: There is an association between cognitive fatigue 
and SDMT, as well as physical fatigue with EDSS pyramidal FS 
score. There is also an association between cognitive and physical 
fatigue and brain atrophy.
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Fatigue evaluation in multiple sclerosis
Saddek Khellaf, Samia Benhamada, Assia Boulefkhad, Yamina 
Sifi, Abderrahim Mzahem and Abdelmadjid Hamri
Department of Neurology, Benbadis University Hospital Center, 
Constantine, Algeria
Background: Several studies showed that fatigue is a symptom 
independent of the neurological deficit intensity in multiple scle-
rosis (MS). The objective of our study was to evaluate the impact 
of various clinical aspects of this overwhelming tiredness, known 
as fatigue, in the daily life of patients with MS.
Methods: This is a cohort study of 68 patients with MS whose 
clinical and epidemiological characteristics were studied. We 
evaluated the fatigue and its impact on the cognitive, physical, 
and psychosocial dimensions, by the Fatigue Impact Scale 
(FIS) and its short version (Modified Fatigue Impact Scale 
(MFIS)). Analysis was performed by SPSS version 20 
software.
Results: FIS and its various dimensions were strongly correlated 
with their MFIS equivalents (r = 0.97, p < 0.001). Fatigue 
(MFIS > 38) was present in 45 patients (66.2%). It was signifi-
cantly correlated with high Expanded Disability Status Scale 
(EDSS; r = 0.36; p < 0.001), advanced age, and long duration of 
illness. Fatigue was more frequent in the progressive (100%) than 
in the relapsing–remitting form (65%, p > 0.05).
Conclusion: The significant correlation between FIS and MFIS 
gives the MFIS a high predictive value. Thus, MFIS can fully 
replace the long version. Fatigue assessment should be an integral 
part of MS management.
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The relationship between demographics of patients with MS 
and the utilization of services provided
Naila Salem AlMazrouei, Omar Abdulla Alteneiji, Palat 
Chirakkara Kumar and Ahmed Osman Shatila
Mafraq Hospital, Abu Dhabi, United Arab Emirates
Background: Multiple sclerosis (MS) is a disabling life-long dis-
ease. It is associated with burden on the health system and patient’s 
life including the economic impacts especially on the young 
patient population. These impacts have not been fully evaluated in 
the Middle East and North Africa (MENA) region though interna-
tional studies have been conducted to determine the causes, inci-
dence, associated risk factors, costs, and its effect on patients with 
MS.
Methods: This study is a descriptive population-based study 
using medical records database system Malaffi at Mafraq Hospital. 
The study protocol was reviewed and approved by the Mafraq 
Research Ethics Committee. All patients with a diagnosis of MS 
who visited the outpatient and inpatient settings in the hospital 
from January 2011 to December 2016 were included. The study 
aimed at identifying the direct costs of MS disease arising from 
diagnosis, management, and treatment. Statistical analysis was 
carried out using STATA software. Data were collected for 109 
patients who used the following services: clinic visits, medica-
tions, hospital admissions, emergency room visits, brain and spine 
magnetic resonance imaging (MRI), laboratory investigations 
(complete blood count (CBC), liver function tests (LFTs), and 
vitamin D) from 2010 to 2016, and sick leaves for the year 2016.
Results: A total of 109 patients of 26 different nationalities were 
identified. The mean age was 34 years (16–64 years). The demo-
graphics consisted of the following characteristics: (1) age: young 
group (up to 19 years) 5%, middle age group (20–50 years) 87%, 
and older group (more than 50 years) 8%; (2) nationalities: 
Emiratis (37.7%) and expats (62.3%); and (3) gender: female 
68.3% and male 31.7%. The frequency of service usage per year 
is as follows: young age 123 accounting for 5.86%, middle age 
1796 accounting for 85.56%, and older age 152 accounting for 
7.24%. From geographical aspects, the Emiratis frequency of ser-
vice usage was 43.64% and Expat’s 56.36%. As for gender, the 
female service usage frequency was 68.75% versus 31.25% for 
the male frequency.
Conclusion: This study assessed the frequency of utilization of 
the medical services by patients with MS. In view of increasing 
awareness and natural rise in cost index, an increase in disease 
burden vis-a-vis expenditure is expected. More research is needed 
to establish a solid plan to minimize and contain the raising eco-
nomic burden of this disease.
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Measles, rubella, and varicella zoster (MRZ) virus reaction 
in CSF of patients with multiple sclerosis compared to other 
CNS inflammatory disorders
Sawsan Feki1, Saba Gargouri2, Sabrina Mejdoub1, Mariem 
Dammak3, Hend Hachicha1, Olfa Hdiji3, Lamia Feki2, Adnen 
Hammami2, Chokri Mhiri3, Hela Karray2 and Hatem Masmoudi1
1Immunology Department, Habib Bourguiba University 
Hospital, Sfax, Tunisia; 2Laboratory of Microbiology, Habib 
Bourguiba University Hospital, Sfax, Tunisia; 3Department of 
Neurology, Habib Bourguiba University Hospital, Sfax, Tunisia
Background: The aim of this study was to investigate the speci-
ficity of measles, rubella, and varicella zoster (MRZ) virus reac-
tion for multiple sclerosis (MS) and to compare it with the 
diagnostic value of oligoclonal bands (OCBs).
Methods: In this study, 158 samples (79 couples of cerebrospinal 
fluid (CSF)/serum) were collected from 79 individuals. Samples 
were analyzed for OCB using CSF isofocusing. Levels of total 
IgG and albumin were determined by nephelemetry for total IgG 
index calculation and Reiber diagram interpretation. MRZ viruses’ 
specific IgG levels were determined using a commercially avail-
able enzyme-linked immunosorbent assay (ELISA) for virus anti-
body determination in CSF and serum. The intrathecal synthesis 
of IgG to MRZ viruses was detected by calculation of the corre-
sponding virus-specific antibody index (AI) according to Reiber’s 
formula. MRZ reaction was considered as positive if at least two 
AIs were ≥1.5. Statistical analysis was performed using SPSS ver-
sion 20 software.
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Results: The MRZ reaction positivity in patients with MS was 
four times as frequent as in control group (65.5% vs 16.6%; 
p < 0.001). The specificity and sensitivity of this reaction for MS 
diagnosis were 83.3% and 65.5%, respectively. As expected, in 
MS group, each of the three specific AIs was found more fre-
quently positive and each median index value was higher in com-
parison with non-MS group. However, the difference reached a 
statistical significance only for R and Z viruses. In addition, the 
RZ reaction was the most prevalent profile among bispecific posi-
tive reactions (12/19). Regarding MS group, MRZ reaction posi-
tivity was significantly associated with the presence of total IgG 
in Reiber diagram (p < 0.001). This association was preserved for 
R and Z viruses when considering each anti-viral reaction alone 
(p < 0.001 and p = 0.001, respectively). The AI values of these two 
viruses were correlated to the total IgG index. Interestingly, in 
OCB-negative MS subgroup, MRZ reaction was detected in 53% 
of patients with a specificity of 92.3% for the disease. Furthermore, 
in OCB-positive patients with MS, the number of bands detected 
in CSF by isofocusing test was correlated to the R-specific AI 
value. The median value of this AI was significantly higher in 
OCB-positive compared to OCB-negative MS group.
Conclusion: Our results confirm that MRZ reaction is overall the 
most specific CSF marker of MS disease and demonstrate its 
interest in diagnosing OCB-negative patients with MS, which 
underline its high potential as a relevant diagnostic marker in 
clinical practice. Especially, the R and Z reactions were found to 
be qualitatively and quantitatively correlated to the IS of total 
IgG. However, the poorly understood pathophysiological role of 
MRZ reaction may require further research.
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Insomnia and disability severity among patients with 
multiple sclerosis in Saudi Arabia
Adel Ali Alhazzani, Noof Mofareh Alamri, Mohammed 
Saeed Alqahtani, Mohammed Saeed Alahmari, Shahad Sahem 
Alkhashrami, Leen Abdulmohsin Sarhan, Muhannad Ali Asiri, 
Abdullmgeed Abdullah Asiri, Reem Ali Alqahtani and Adel Ali 
Alfaifi
King Khalid University, Abha, Saudi Arabia
Background: Sleep disturbance is common among patients with 
multiple sclerosis (MS). Patients are in a vicious circle where both 
their physical and mental state may depend on or lead to sleep 
disorders and many health problems such as physic disability. In 
this study, our objective was to assess the insomnia and disability 
severity among patients with MS.
Methods: This study was conducted among a sample of 598 
patients with MS resident in five regions in Saudi Arabia and 
between 15 and 60 years of age. To assess participants’ demo-
graphic characteristics, disease-related factors, detected 
depression and medication adherence, and their association 
with insomnia and disability severity, this survey was con-
ducted among consenting participants by a self-administered 
questionnaire that involves four validated scores (Insomnia 
Severity Index (ISI), Patient Determined Disease Steps 
(PDDS), Patient Health Questionnaire-9 (PHQ-9), and 
Morisky score). We used SPSS version 22 to analyze the data 
by applying chi-square test and one-way analysis of variance 
(ANOVA) tests.
Results: About 35.8% of the responders were male and 64.2% 
were female. The mean age at the time of diagnosis was 26.1 
(±7.9) years, and the mean disease duration was of 6.7 (±6.2) years. 
The mean number of attacks in the past 2 years was of 2 (±2) 
attacks. Among responders, 23.1% were suffering from moderate 
to severe insomnia, 11.4% were suffering from advanced disabil-
ity, and 50.5% from major depression. A total of 59.9% had low 
adherence to MS treatment. Overall, demographic and the remain-
ing studied variables were significantly associated with the level 
of insomnia and the level of disability.
Conclusion: Awareness programs should be conducted in order 
to improve quality of life of patients with MS and to prevent 
physical and mental health problems which are frequent in MS 
population.
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Treatment adherence and satisfaction among patients with 
multiple sclerosis, Saudi Arabia: Cross-sectional study
Adel Alhazzani, Mohammed Saeed Alahmari, Mohammed 
Saeed Alqahtani, Muhannad Ali Asiri, Noof Alamri, Leen 
Sarhan, Shahad Alkhashrami and Adel Alfaifi
King Khalid University, Abha, Saudi Arabia
Background: Multiple sclerosis (MS) is an unpredictable, inflam-
matory, chronic disease. Adherence to disease-modifying therapy 
(DMT) is necessary to achieve improvement in clinical benefit. 
The objective of this study was to examine the association between 
adherence to medication and treatment satisfaction in patients 
with MS living in Saudi.
Methods: A cross-sectional study was carried out to assess 
treatment satisfaction and DMT adherence in patients with MS 
recruited from outpatient clinics of tertiary hospitals of five 
regions (south, east, west, middle, and north) in KSA. All 
patients answered a questionnaire regarding their MS treatment 
satisfaction, and the common Morisky Medication Adherence 
Scale (MMAS-8) was used to assess patient adherence. Patient 
Determined Disease Steps (PDDS) was used to measure disabil-
ity. Data were analyzed using descriptive statistics, Mann–
Whitney test, Kruskal–Wallis test, and Spearman’s coefficient 
correlation.
Results: Of the 598 patients with MS studied, 384 (64.2%) 
were female. In all, 310 (51.8%) were married. Mean age was 
32.4 years (standard deviation (SD) = 8.4 years). Mean age at 
disease onset was 26.9 years (SD = 7.6 years). The mean dura-
tion of illness was 6.5 years; the mean number of admission was 
1.4 times (SD = 1.7 times). Almost 60% had low adherence and 
80% of causes were due to presence of attacks and side effects. 
The mean treatment of satisfaction was 76.2. Treatment satis-
faction was positively correlated with DMT adherence 
(r = 0.268, p = 0.000) and negatively correlated with PDDS 
(r = −0.232, p = 0.000). No statistical correlation was found 
between PDDS and DMT adherence. Marital status and educa-
tional level were significantly associated with DMT adherence 
at a level of significance of 0.05.
Conclusion: The study concluded that patients with MS have low 
adherence because of the occurrence of attacks and side effects of 
DMT. Treatment satisfaction was not the only cause for DMT 
adherence. Most differences were found with respect to side 
effects and convenience of treatment.
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Quality-of-life assessment among patients with multiple 
sclerosis, Saudi Arabia: Cross-sectional study
Mohammed Saeed Alqahtani, Adel Alhazzani, Mohammed 
Saeed Alahmari, Muhannd Asiri, Shahad Alkhashrami, Leen 
Sarhan, Noof Alamri and Abdullmajeed Asiri
King Khalid University, Abha, Saudi Arabia
Background: Multiple sclerosis (MS) is an unpredictable, inflam-
matory, chronic, and potentially disabling neurological disease 
that is very common in young adults. The aim of this study is to 
determine the health-related quality of life (QoL) among patients 
with MS living in Saudi Arabia.
Methods: A cross-sectional study was carried out to assess the 
QoL of patients with MS. Patients were recruited from outpatient 
clinics of tertiary hospitals in five regions (south, east, west, mid-
dle, and north). Clinical and demographic data were collected, as 
well as information on patients’ health status using the Arabic 
translation of the self-reporting 36-Item Short-Form (SF-36) 
questionnaire to assess QoL. The Patient Determined Disease 
Steps (PDDS) was used to measure disability. Data were analyzed 
using descriptive statistics, Mann–Whitney test, Kruskal–Wallis 
test, and Spearman’s coefficient correlation.
Results: Of the 598 patients with MS studied, 384 (64.2%) were 
female. The mean score for males was higher than for females in all 
SF-36 QoL subscales. The mean age was 32.4 years (standard devia-
tion (SD) = 8.4 years). The mean age at disease onset was 26.9 years 
(SD = 7.6 years). The mean duration of illness was 6.5 years; the 
mean number of admissions was 1.4 (SD = 1.7). Patients had the low-
est scores in role motioning/emotional scale (mean = 42.6, SD = 43.3). 
The PDDS was negatively correlated with all SF-36 QoL subscales. 
SF-36 QoL for patients with MS differs significantly through demo-
graphic characteristics at a level of significance of 0.05.
Conclusion: This study concluded that patients with MS have a 
low QoL score and need more interests. Further development of 
the registration will provide access to the entire population of 
patients with MS and help comprehensively analyze the factors 
that affect the quality of their lives.
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Depression severity among patients with multiple sclerosis in 
Saudi Arabia
Adel Ali Alhazzani1, Reem Ali AlQahtany1, Mohammed Saeed 
Alqahtani1, Abdullmgeed Abdullah Asiri1, Muhannad Asiri1, 
Adel Ali Alfaifi1, Hassan Abdulrahman Ogran2, Abdulrahman 
Yahya Asiri2, Ali Mohammed Al-Hanash2 and Osamah Hussain 
Abuhawi3
1King Khalid University, Abha, Saudi Arabia; 2Medical 
Department, Asser Central Hospital, Abha, Saudi Arabia; 
3Department of Pathology, King Faisal Specialist Hospital & 
Research Center, Jeddah, Saudi Arabia
Background: Our study aimed to assess depression severity 
among patients with multiple sclerosis (MS).
Methods: Our survey was carried out among a sample of 598 
male (35.8%) and female (64.2%) patients with MS, Saudi and 
non-Saudi, from five different regions in KSA, between 15 and 
60 years of age. We used a self-administered questionnaire that 
was developed specially for this study after consulting literature. 
The data were verified and analyzed using SPSS version 22.
Results: The mean patient age at the time of diagnosis was 26.1 
(±7.9) years. The mean duration of the disease was 6.6 (±4.8) years. 
More than a quarter of patients (27.1%) were admitted in the last 
year. Our results revealed that 9.7% of participants had family 
history of MS, and 27.8% of respondents were suffering from dif-
ferent chronic diseases. A large proportion of patients were receiv-
ing drugs for MS (interferon beta (IFNβ) in 26.2% of patients). 
Among respondents, the majority (53.2%) were likely to have 
mild level of disability and mild depression severity (30.8%). Chi-
squared test revealed significant relationship between level of dis-
ability and depression severity.
Conclusion: To cope with MS disease, patients should be educated 
and encouraged to adopt healthy habits and receive cognitive 
behavioral therapy helping them to ensure a better quality of life.
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Human leukocyte antigen (HLA) typing in Iraqi patient with 
multiple sclerosis (MS)
Maytham Fadhil Jalal, Anmar Oday Hatem and Eman Sh Al-
Obeidy
University of Baghdad, Baghdad, Iraq
Background: Multiple sclerosis is a demyelinating disease of the 
central nervous system with a presumed autoimmune etiology. 
The etiology of MS remains unclear, but according to current data 
the disease develops in genetically susceptible individuals and 
may require additional environmental triggers. The human leuko-
cyte antigen (HLA) Class II alleles may have the strongest genetic 
effect in MS. Such associations have not been as clearly defined 
in many Arab populations, where even the frequencies of specific 
HLA antigens remain unclear. The study was designed to (1) study 
the HLA of Classes 1 and 2 in a multiple sclerosis (MS) popula-
tion to verify the susceptibility for the disease in Iraqi Arab 
patients and (2) assess possible inter-relationships between HLA 
Class II antigens and clinical phenotypic variables in MS such as 
age at onset and gender.
Methods: Peripheral blood was collected from 100 patients with 
MS. McDonald’s criteria were used for MS diagnosis. We sup-
plied a questionnaire containing questions about parameters such 
as age, gender, ethnicity, positive family history, as well as sub-
type of MS; however, clinical parameters’ estimation was carried 
out by 100 healthy individuals, without any autoimmune disease 
and familial history of MS, selected as control group. Controls 
were originally from the same geographical region and were 
matched with cases in ethnicity. HLA Class I (A, B) and Class II 
(DRB1*, DQB1*) antigens’ tissue-typing was performed by pol-
ymerase chain reaction (PCR) amplification with sequence-spe-
cific primers (PCR-SSP) method in two groups of age- and 
sex-matched Iraqi subjects: (1) 75 patients with definite MS (52 
relapsing–remitting and 23 relapsing-progressive) and (2) 100 
healthy controls. The frequencies of specific HLA types were 
then compared between patients with controls, and in the former 
related to specified clinical parameters.
Results: As mentioned above, HLA Class I (A, B) and Class II 
(DRB1*, DQB1*) allele was evaluated among 100 patients with 
MS and 100 healthy age- and sex-matched individuals. The fre-
quencies for Class I antigens—A*0901, A*0602, and B*0501—
appeared higher with the presence of MS. For Class II antigens, 
frequencies of DRB1*0401, DRB1*1501, and DQB1*0502 were 
increased in patients with MS. HLA type DRB1*0401 was present 
MENACTRIMS Abstracts NP27
Multiple Sclerosis Journal 2018 NP27–NP30journals.sagepub.com/home/msj
at higher frequencies in patients with a younger age at disease 
onset and in female patients.
Conclusion: This is the first report on HLA association with MS in 
Iraqi population using high-resolution sequence. There is a trend 
toward an association between HLA Class I antigens (A*0901, 
A*0602, B*0501) and Class II antigens (DRB1*0401, DRB1*1501, 
and DQB1*0502) and MS in Iraqi subjects. Additionally, it 
appeared that DRB1*0401 was more frequent in females and those 
with an early onset of the disease. This work is still in progress as 
we analyzed more patients with MS and normal control.
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Prevalence of transverse myelitis and neuromyelitis 
optica spectrum disorders in the United Arab Emirates: A 
retrospective, multi-center study
Faisal Aziz1, Kathryn B Holroyd2, Michael Levy3, Miklos 
Szolics4, Taoufik Alsaadi5 and Nicoline Schiess3
1UAE University, Al Ain, United Arab Emirates; 2Brigham and 
Women’s Hospital, Boston, MA, USA; 3Department of Neurology 
and Neurosurgery, Johns Hopkins University, Baltimore, MD, 
USA; 4Department of Neurology, Tawam Hospital, Al Ain, 
United Arab Emirates; 5American Center for Psychiatry and 
Neurology, Abu Dhabi, United Arab Emirates
Background: Transverse myelitis (TM) is an inflammatory syn-
drome of the spinal cord presenting with weakness, sensory loss, and 
bowel/bladder dysfunction. TM can occur as a monophasic condi-
tion or as part of a relapsing disease often associated with neuromy-
elitis optica spectrum disorders (NMOSDs). The incidence and 
prevalence of both TM and NMOSD in the Middle East is unknown.
Objective: To determine the prevalence and characteristics of TM 
and NMOSD in Abu Dhabi, United Arab Emirates.
Methods: This is a retrospective chart review conducted at four 
large government-run hospitals in Abu Dhabi Emirate between 
2010 and 2016. Data collected included year of onset, presenta-
tion, laboratory results including anti-NMO/myelin oligoden-
drocyte glycoprotein (MOG) antibodies, and occurrence of any 
relapses.
Results: In all, 46 subjects were identified with either TM or 
NMOSD with 23 (50%) of them being national Emirati citizens. 
Within the overall group including pediatrics, the crude preva-
lence rate for monophasic TM was 1.0 and for NMOSD was 
0.34/100,000. For the Emirati citizens age 20 years and above, the 
prevalence rate for monophasic TM was 2.46 and 1.76 for 
NMOSD. The whole group adult (≥20 years) prevalence rate was 
1.00 for TM and 0.39 for NMOSD. The mean age was 
42 ± 17.6 years with a mean age of onset of 37 ± 18 years and 54% 
were female. In the Emirati subgroup, 83% were female. Nine 
patients overall had a positive anti-NMO or anti-MOG antibody 
result, of which six of nine (66%) were Emirati citizens. Of the 30 
subjects with available laboratory cerebrospinal fluid (CSF) anal-
ysis, 36.6% had elevated white blood counts (>5.0 × 106/L) and 
43% had elevated protein levels. Of the 19 subjects with docu-
mentation of oligoclonal bands (OCBs) or IgG index, only 4 
(21%) had either OCB or elevated IgG index.
Conclusion: This is one of the few studies describing the preva-
lence, epidemiology, and characteristics of TM and NMOSD 
among population in the Middle East demonstrating an adult prev-
alence rate for Emirati citizens of 2.46 for monophasic TM and 
1.76 for NMOSD.
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Concurrent central and peripheral demyelination-CIDP and 
RRMS: A case report
Rasha Hussein Mohammed Ibrahim, Pournamy Sarathchandran 
and Jihad Said Inshasi
Rashid Hospital, Dubai Health Authority, Dubai, United Arab 
Emirates
Background: Demyelinating diseases usually affect either the 
central nervous system (CNS) or peripheral nervous system 
(PNS). CNS and PNS demyelinating diseases rarely occur in same 
individual. There are few case reports about central and peripheral 
demyelination occurring simultaneously or sequentially.
Case report: This is the case of a 48-year-old lady who has been 
diagnosed with relapsing–remitting multiple sclerosis (RRMS) 
since age 27 years. She presented initially with unsteadiness of 
gait followed by motor and sensory symptoms over 2 years. She 
was initiated on interferon beta 1a injections, which was escalated 
to fingolimod due to clinical and radiological relapses. In May 
2015, 20 years after the onset of MS, while on fingolimod, she 
noticed bilateral lower limb weakness, with examination reveal-
ing areflexic weakness with distal sensory loss. Magnetic reso-
nance imaging (MRI) of brain and spine with contrast did not 
show any new lesion. Nerve conduction study showed demyeli-
nating sensory and motor polyneuropathy, with conduction blocks 
affecting her lower limbs more than upper limbs. She was diag-
nosed as chronic inflammatory demyelinating polyneuropathy 
(CIDP), and intravenous (IV) immunoglobulin (IG) was started, 
following which her symptoms resolved. Currently, she is receiv-
ing monthly bolus IV IG with no more exacerbation of CIDP or 
MS for the last 2 years.
Conclusion: Association of CIDP with multiple sclerosis is rare; 
however, it needs to be recognized early, as it is a treatable dis-
ease. Thorough examination should be performed in patients with 
MS presenting with neurological deterioration to differentiate 
relapses from peripheral demyelination. Absence of MRI lesions 
should not be diagnosed as pseudo relapse unless other causes of 
neurological deterioration are ruled out.
72
Highlights on cyclophosphamide effect in active relapsing–
remitting multiple sclerosis
Magd Fouad Zakaria, Mahmoud Saad Swelam, Dina AbdEl-
Gawad Zamzam, Ayman Mohamed Nasef, Samia Ashor Helal, 
Mohamed Aly Abdel Hafeez, Alaa Mohamed Abou Steit, 
Shaimaa Sayed Khater, Mohamad Mahmoud Fouad, Ayman 
Abdel Hady and Mohamed Hamdi Attia
Faculty of Medicine, Ain Shams University, Cairo, Egypt
Background: Cyclophosphamide (CYC) is an alkylating agent 
which produces immunosuppression and an anti-inflammatory 
immune deviation. CYC is used extensively in treating aggressive 
and rapidly progressive forms of multiple sclerosis (MS), with 
mixed results. The aim of this exploratory prospective study was 
to determine the effect of CYC therapy given to active form of 
patients with relapsing–remitting MS (RRMS) for better control 
of clinical disease activity regarding relapse rate, disease progres-
sion, and radiological outcome.
Methods: In all, 69 patients with active RRMS were treated and 
followed up for a period of 12 months. Totally, 22 patients 
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received monthly pulse doses of CYC with starting dose of 
800 mg/m2 with dose augmentation to induce leukopenia of 3000/
mm3 and/or lymphopenia of 800/mm3 guided by complete blood 
picture 14 days after each dose plus 1 g of methylprednisolone; 23 
patients received subcutaneous interferon beta-1a 44 IU three 
times weekly; and 24 patients received monthly methylpredniso-
lone only. The primary outcome measure was annual relapse 
reduction, stabilization of disease progression (measured by 
Expanded Disability Status Scale (EDSS)), and decreased mag-
netic resonance imaging (MRI) activity measured by the presence 
of new T2 lesions and/or gadolinium-enhancing lesions at the end 
of study and during relapses as secondary outcome measure.
Results: At 12th month of therapy, CYC produced significant 
relapse reduction compared to pretreatment baseline state 
(p < 0.001) and to monthly methylprednisolone group (p = 0.03) 
with relative risk reduction equal to 80.2%. In comparison to 
interferon beta-1a, there was no significant difference (p = 0.46). 
CYC induced significant improvement in disability previously 
accumulated compared to pretreatment baseline state (p < 0.001), 
but no significant difference between groups (p = 0.2). Significant 
reduction in gadolinium-enhancing lesions (p < 0.004) was 
reported in CYC patients compared to pretreatment baseline state, 
but no significant difference between groups (p = 0.06).
Conclusion: CYC showed significant clinical and radiological 
beneficial effect on controlling RRMS activity.
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Outcomes of Iraqi patients with multiple sclerosis treated 
with natalizumab
Akram M Al-Mahdawi, Anmar Oday Hatem and Omar Tahseen 
Mohammed
Baghdad Teaching Hospital, Baghdad, Iraq
Background: Multiple sclerosis (MS) is a chronic heterogeneous 
demyelinating axonal and inflammatory disease involving the central 
nervous system (CNS) white matter with a possibility of gray-matter 
involvement in which the insulating covers of nerve cells in the brain 
and spinal cord are damaged. This damage disrupts the ability of parts 
of the nervous system to communicate, resulting in a wide range of 
signs and symptoms. Natalizumab is used to treat adults with relaps-
ing forms of MS to slow the worsening of symptoms common in 
people with MS and to decrease the number of relapses.
Methods: This is a cross-sectional study that enrolled 72 patients. 
The study was conducted in Baghdad teaching hospital in MS clinic 
from April 2015 to December 2016. The medical charts of all 
patients with MS admitted to Baghdad hospital to receive natali-
zumab infusion were reviewed. Data about any new neurological 
symptoms, disability progression measured by Expanded Disability 
Status Scale (EDSS), and new lesions on brain magnetic resonance 
imaging (MRI) with contrast (T1, T2, three-dimensional fluid atten-
uated inversion recovery (FLAIR), T1 with contrast) were col-
lected. The diagnosis of MS was made according to the 2010 
McDonald’s criteria.
Results: Mean age of patients was 32.5 ± 8.1 years, with a 
female-to-male ratio of 1.7:1. Half of the patients were unem-
ployed, and 30% of them were working currently. Overall, 51 
(70.8%) patients had no new clinical attacks. A total of 72.2% of 
the patients had no new MRI lesions. There was significant 
reduction in EDSS; however, despite this significant reduction in 
EDSS, it was modest (median change was 0.25, 5.88% reduction) 
that only 5.6% of the patients had decline in their EDSS. There 
was a strong inverse relationship between EDSS change and 
number of doses which indicate that as the number of doses 
increases there is a reduction in EDSS.
Conclusion: Our study provides evidence that natalizumab sig-
nificantly reduces the progression of disability, the occurrence of 
clinical relapse, and the appearance of new MRI.
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Epstein–Barr virus antibodies in a sample of Egyptian 
patients with relapsing–remitting multiple sclerosis
Dina Mohammad AbdElgawad Zamzam, Azza Abdel Nasser 
Abdel Aziz, Mohamad Mahmoud Fouad, Aya Helal Mahmoud, 
Mohamed Aly Abdel Hafeez, Mahmoud Saad Swelam, Alaa 
Mohamed Abou Steit, Shaimaa Sayed Khater, Nouran Mohamed 
Salah, Amira ElHussien Mahmoud and Hend Ali Ahmed
Faculty of Medicine, Ain Shams University, Cairo, Egypt
Background: An association between Epstein–Barr virus (EBV) 
and multiple sclerosis (MS) has always been postulated. This 
study aims to detect the association of EBV as a risk factor of MS 
in a sample of Egyptian patients and its relationship to the clinical 
and radiological features of the disease.
Methods: In all, 86 Egyptian patients with the diagnosis of 
relapsing–remitting MS (RRMS) were recruited consecutively 
from MS Unit of Neurology Department at Ain Shams 
University Hospital and were compared to 64 healthy age- and 
sex-matched controls in this case–control prospective observa-
tional study. Patients’ medical history and general and neuro-
logical examination including assessment of the functional 
disability using Expanded Disability Status Scale (EDSS) were 
obtained, and all subjects underwent serum sampling for detec-
tion of the anti-EBV IgG antibodies using enzyme-linked 
immunosorbent assay (ELISA) technique.
Results: Data showed that 92.9% of the patients had positive anti-
EBV antibodies compared to 30.3% of the controls (p < 0.001) 
detected. The seropositive patients had significantly longer dura-
tion of illness (p = 0.024), higher number of relapses (p = 0.026), 
and higher EDSS scores (p = 0.001). While EBV antibody titer 
was significantly directly correlated to the duration of illness 
(p = 0.014).
Conclusion: These data together with earlier reports strengthen 
the hypothesis that EBV infection or the immune response to EBV 
antigens has a potential role in pathogenesis of MS illness and 
progression of the disease.
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Human herpes virus-6 as a risk factor of relapsing and 
remitting multiple sclerosis in a sample of Egyptian patients
Dina Abd El-Gawad Zamzam, Mahmoud Haroon Ibrahim, 
Ahmed Mohamed Elsadik, Saif Eldin Salah Youssef, Mohamad 
Mahmoud Fouad, Mohamed Aly Abdel Hafeez, Mahmoud Saad 
Swelam, Alaa Mohamed Abou Steit, Shaimaa Sayed Khater, 
Amira ElHussien Mahmoud and Hend Ali Ahmed
Faculty of Medicine, Ain Shams University, Cairo, Egypt
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Background: Multiple sclerosis (MS) is a chronic autoimmune 
illness of the central nervous system which is considered the most 
common non-traumatic cause of neurological disability in middle 
age. Numerous techniques have been used to investigate the pos-
sible association between human herpes virus-6 (HHV-6) and MS. 
This study aims to detect the possible association of HHV 6 as a 
risk factor of MS disease in a sample of Egyptian patients.
Methods: A total of 90 Egyptian patients were included in our 
sample from MS unit patients’ records from the Neurology 
Department at Ain Shams University Hospital with relapsing–
remitting MS (RRMS) type. In all, 60 healthy controls matching 
the patients in age and sex were added to the study for correla-
tions. Patient’s medical history and general and neurological 
examination including assessment of MS according to the Revised 
McDonald criteria for MS diagnosis and functional disability 
using Expanded Disability Status Scale (EDSS) were assessed at 
admission. All subjects underwent serum sampling for detection 
of anti-HHV-6 IgG using enzyme-linked immunosorbent assay 
(ELISA) technique.
Results: Highly significant correlation in the IgG response of 
patients with RRMS to antigen of HHV-6 compared to that of 
normal controls (p < 0.001) was detected. Other clinical deter-
ments for MS course and progression showed a high significant 
association between duration of illness of MS and the presence of 
HHV-6 IgG in serum (p = 0.009) and a significant association 
between the total number of relapses and presence of HHV-6 IgG 
in serum (p = 0.011).
Conclusion: Our data together with earlier reports strengthen the 
hypothesis that HHV-6 infection or the immune response to 
HHV-6 antigens has a potential etiological role in MS illness. 
Awareness of this relation between MS and HHV-6 infection 
might improve early diagnosis of MS and improve researches for 
curative treatment.
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Fulminant multiple sclerosis, what to do? Diagnostic 
approach and management options
Motaz Gafer Mohammed Helali and Riham Hassan Mohammed 
Abdelrahman
King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
Background: Fulminant multiple sclerosis (MS) is the most 
aggressive type of MS, which typically leads to great disability 
and even death within weeks. It is usually monophasic and repre-
sents a medical emergency that calls for urgent management. 
Fulminant MS includes two variants, Marburg type and Balò con-
centric sclerosis. The Marburg type, which also called tumefactive 
MS, is characterized by tumor-like demyelinating brain lesions 
while the Balò subtype is characterized by concentric layers of 
alternate myelination and demyelination.
Methods: A systematic literature review has been done to identify 
the cases of fulminant MS. Our objectives were to evaluate the 
diagnostic strategies and therapeutic approach and to highlight the 
characteristic clinical, pathological, and radiological features of 
fulminant MS.
Results: (1) Pathological features: Balò’s variant was character-
ized by alternate concentric layers of demyelination and 
preserved myelin. While the Marburg subtype was characterized 
by demyelination associated with profound inflammation, 
tissue destruction, necrosis, and macrophage infiltration. (2) 
Presentation: fulminant MS is more common in young and usu-
ally monophasic. The symptoms may start with fever in some 
cases followed by a decreased level of consciousness and focal 
neurological deficit. Seizure has also been reported. Peripheral 
nervous involvement has also been reported in some cases of 
Marburg subtype. (3) Magnetic resonance imaging (MRI) with 
contrast: the Marburg variant is characterized by large lesions of 
tumefactive demyelination with mass effect and incomplete ring 
enhancement, but rarely presented with disseminated small 
demyelinating lesion. Remyelination of affected areas is rare. 
While in Balò concentric sclerosis, round lesions with irregular 
concentric rings of low and high signal alternate to give the 
onion bulb appearance. Peripheral enhancement indicates active 
demyelination. It may also be associated with peripheral diffu-
sion restriction.
Conclusion: Fulminant MS is a rare type of MS which has a 
grave prognosis especially if not diagnosed and treated promptly 
and appropriately. Other fulminant demyelinating disorders as 
well as viral encephalitis, progressive multifocal leukoencepha-
lopathy (PML), high-grade gliomas, and lymphomas need to be 
excluded. 
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Vitamin B12 and its impact on multiple sclerosis type and 
severity
Shymaa Buhlaiqah1, Omer M Salih1, Fahad Nassim Ali2, Reem 
Fahad Bunyan1, Talal Mutib Alharbi1 and Eman Nassim Ali1
1King Fahad Specialist Hospital-Dammam, Dammam, Saudi 
Arabia; 2Johns Hopkins Aramco Healthcare, Dhahran, Saudi 
Arabia
Background: Cyanocobalamin (vitamin B12) deficiency is con-
sidered an important multiple sclerosis (MS) mimic; this is due to 
the similarities clinically and pathophysiologically of both dis-
eases, as both attack the myelin sheath of the nervous system. The 
study aimed to determine the association between vitamin B12 
levels and MS type and severity.
Methods: This is a retrospective single-center study of patients 
seen at the specialized MS clinics. Data were obtained through the 
MS database for a total of 350 patients. Patients were divided into 
either relapsing–remitting MS (RRMS) or progressive MS 
(PRMS). Vitamin B12 values were obtained at the first visit and a 
cutoff value of 200 pg/mL or above was considered normal. The 
severity of MS was evaluated using the Extended Disability Status 
Scale (EDSS). Fisher’s exact test was used to identify whether 
vitamin B12 levels distinguished between MS types. Local regres-
sion was used to assess the correlation between vitamin B12 lev-
els and the EDSS.
Results: A total of 100 patients with MS had vitamin B12 lev-
els (91 RRMS and 9 PRMS) with a 1:1.5 male-to-female ratio. 
B12 levels were below normal in 30 RRMS cases and 1 SPMS 
case (p = 0.27). Local regression showed an inverse relation 
between vitamin B12 levels and EDSS at the sub-therapeutic 
levels; this relation plateaued once the therapeutic levels were 
reached.
Conclusion: Low vitamin B12 levels were inversely correlated 
with MS disability measures but failed to distinguish between MS 
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types. The small sample size of PRMS was considered a limitation 
in our study. Future studies looking at the effects of vitamin B12 
on MS severity are needed.
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Spectrum of primary headaches in multiple sclerosis
S Mrabet, Y Sidhom, A Souissi, A Nasri, A Gargouri, M 
BenDjebara and R Gouider
Department of Neurology/Research Unit UR12SP21, Razi 
Hospital, Tunis, Tunisia
Background: Headache is not considered as a symptom of multi-
ple sclerosis (MS). However, several studies have shown a rela-
tionship between these two diseases.
Objective: To study the frequency, characteristics, and timing of 
primary headache in patients followed for MS.
Methods: This is a retrospective study including patients fol-
lowed for MS in the Neurology Department at the Razi Hospital 
between July and December 2016. For each patient, we collected 
anamnestic, clinical, and radiological data. The information col-
lected from the patients’ medical records were placed on fact 
sheets and analyzed by Excel.
Results: In all, 50 patients were identified: 22 men and 28 women. 
The frequency of headache was present in 82%. Migraine head-
aches were present in 54%, tension in 39%, and trigeminal neural-
gia in 6%. For migraine headaches, we noted 20% with aura and 
the remainder without aura. Cerebro-medullary imaging showed 
subcortical lesions in 62.5%, periventricular lesions in 92.5%, 
brain stem lesions in 65%, and medullary lesions in 65%. There 
was an exacerbation of headaches’ frequency after the diagnosis 
of MS in 60%.
Conclusion: Most headaches during MS are migraine. They 
are more frequent in women than in men. There has been an 
increase in the frequency of migraine attacks during MS most 
likely due to inflammation. The predominant radiological 
lesions are periventricular which are most predictable of caus-
ing headache.
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Uhthoff phenomenon in multiple sclerosis in a Tunisian 
cohort
S Mrabet, J Ketata, A Nasri, Y Sidhom, A Gargouri, M 
BenDjebara and R Gouider
Department of Neurology/ Research Unit UR12SP21, Razi 
Hospital, Tunis, Tunisia
Background: The Uhthoff phenomenon is common in multiple 
sclerosis (MS). Few studies have examined this phenomenon in 
Africa.
Objective: To evaluate the incidence and clinical characteristics 
of the Uhthoff phenomenon in Tunisian patients with MS.
Methods: We used a questionnaire for patients with MS followed 
in the Neurology Department at the Razi Hospital (Tunisia), from 
1 October to 30 November 2016, concerning transient and brief 
neurological symptoms triggered and/or aggravated by an increase 
in body temperature. We have included patients with an Uhthoff 
phenomenon. Their symptoms were classified as motor (weak-
ness, disturbance of balance), sensory (numbness, tingling, burn-
ing), visual (blurred vision, diplopia), and vesicosphincter (urinary 
incontinence).
Results: In all, 57 patients were included with an average age of 
38.6 years. The Uhthoff phenomenon was noted in 61.4% of 
patients with predominant motor symptoms (71.4%) followed by 
visual symptoms (48.5%) and sensory symptoms (37.1%). About 
22 patients had two or more types of symptoms. Symptoms 
occurred after 3–60 minutes (standard deviation (SD) = 18.3 min-
utes) and disappeared completely after 5 minutes to 3 hours 
(SD = 45.2 minutes). Walking was the primary trigger (62.8%).
Conclusion: The frequency of the Uhthoff phenomenon has not 
been studied in African countries. Indeed, our study has shown a 
high frequency according to Asia (48.1%) and Western (80%) 
countries. The main triggering factor is exercise as walking was 
most common in our study. Temperature-dependent central motor 
conduction blockage of partially demyelinated axons has been 
proposed as the main pathophysiological mechanism.
